Novel camptothecin analogue ligand-drug conjugate, intermediate, pharmaceutical composition and application of novel camptothecin analogue ligand-drug conjugate
By optimizing the structure of camptothecin analogues' ligand-drug conjugates, the problem of their low solubility in antibody-drug conjugates was solved, achieving efficient and stable cancer treatment effects and reducing side effects.
Patent Information
- Application Number
- CN202410569685.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-10
- Filing Date
- 2024-05-09
- Publication Date
- 2024-11-12
AI Technical Summary
Existing camptothecin compounds have low solubility in antibody-drug conjugates, leading to aggregation and systemic side effects, which limits their application in cancer treatment.
A series of camptothecin analogues ligand-drug conjugates were developed. By optimizing the structure of the linker and drug unit, the stability of the compounds in circulation was improved, and camptothecin analogues were efficiently released into disordered cells to achieve high cytotoxicity.
It improved the solubility and stability of camptothecin analogues in antibody-drug conjugates, enhanced the targeted therapeutic effect on cancer cells, and reduced systemic side effects.
Smart Images

Figure BDA0004830464060000021 
Figure BDA0004830464060000031 
Figure BDA0004830464060000032
Abstract
Description
Technical Field
[0001] The present application provides a conjugate of a camptothecin analog and a cell-surface receptor-binding molecule for targeted therapy, and a pharmaceutical composition comprising such a conjugate. The present application also provides a camptothecin analog, an intermediate of the conjugate of the camptothecin analog, and a method for preparing the same. The present application also provides the use of a camptothecin analog, a conjugate of a camptothecin analog, a pharmaceutical composition comprising a camptothecin analog, and a pharmaceutical composition comprising a conjugate of a camptothecin analog and a cell-binding molecule for targeted therapy of cancer. Background Art
[0002] Cancer is the leading cause of death worldwide. Surgery, chemotherapy, radiotherapy, and targeted therapy are the standard of care treatments. Despite its widespread use, the use of most chemotherapies is limited by adverse side effects, primarily through effects on cells outside the tumor and its environment, leading to systemic toxicity and a narrow therapeutic window. The discovery of the unique composition of cancer cell surfaces, combined with an understanding of the strong and selective interactions between antibodies and cell surface antigens, has paved the way for the use of antibodies as targeted delivery agents for chemotherapy, including highly toxic drugs (Drago, JZ et al., Nat. Rev. Clin. Oncol. 2021.; Khongorzul, P. et al., Mol. Cancer Res. 2020, 18, 3–19.; Joubert, N. et al.; The Last Decade. Pharmaceuticals 2020, 13, 245.; Ravi VJ Chari et al., Angew. Chem. Int. Ed. 2014, 53, 3796–3827.). The resulting molecular entity, also known as an antibody-drug conjugate (ADC), consists of three main parts: an antibody responsible for selectively recognizing cancer cell surface antigens that enable internalization of the ADC, a drug payload responsible for killing cancer cells once released into the body, and a linker that connects the antibody and payload moieties.
[0003] Antibody-drug conjugates (ADCs) combine selective targeting of tumor cells through antigen-directed recognition and potent cell-killing through cytotoxic payloads, and have become effective therapeutic approaches for treating various cancers in recent years (Nature review drug discovery, 2013, 12, 329-332). The first ADC (Mylotarg) was approved in 2000 (re-approved in 2017 after being delisted in 2010), the second ADC (Adcetris) was approved under accelerated approval in 2011, and fully approved in 2015. The third (Kadcyla) and fourth (Besponsa) ADCs were approved in 2013 and 2017, respectively. Kadcyla is the first ADC approved for the treatment of solid tumors. Since 2019, more than a dozen ADCs have been approved, and more than 100 ADCs are in clinical development.
[0004] It is known that the payload-linker component in ADC plays a key role in the uniformity, circulation stability, pharmacokinetic characteristics, tolerability and overall therapeutic effect of ADC (Acchionea, M. et al., mAbs. 2012, 4, 362.; Zhao, RY et al., J. Med. Chem. 2011, 54, 3606). Despite extensive research to improve these properties, most payloads used to date include DNA damaging agents (such as calicheamicin, PBD, and duocarmysins), microtubule disruptors (such as maytansines, such as DM1 or DM4; aureumistatins, such as MMAE or MMAF; tubulysins), and topoisomerase inhibitors (such as camptothecins, such as Dxd or SN-38) (Leung, D., et al., Antibodies (Basel). 2020, 9, 2.; Khongorzul, P., et al., Mol. Cancer. Res., 2020, 18, 3.; Chau, CH, et al., Lancet. 2019, 394, 793.).
[0005] Among these payloads, camptothecin compounds have been shown to be a promising option with a wider therapeutic index than many other payloads constructed for ADC. Two approved ADCs, Enhertu and Trodelvy, use camptothecin payloads Dxd and SN-38, respectively, and have demonstrated significant clinical benefits (progression-free survival (PFS) and overall survival (OS)) for solid tumors in many clinical trials (Pondé, N., et al., Curr Treat Options Oncol. 2019, 20, 37.; Kaplon, H., et al., Mabs. 2020, 12, 1703531.). Camptothecin can induce cell death by interacting with the DNA enzyme topoisomerase I and then accumulating a reversible enzyme-camptothecin-DNA ternary complex.
[0006] Camptothecin is a potent antitumor antibiotic isolated in 1958 from an extract of Camptotheca acuminata, a plant that has been widely used in traditional Chinese medicine for hundreds of years. Many camptothecin analogs have been disclosed, such as those shown below:
[0007] Camptothecin and most of its analogs are extremely insoluble in physiological buffers and have shown high adverse drug reactions in preliminary clinical trials since the 1970s. The low solubility of camptothecin can cause their ADC conjugates to aggregate (Burke, P., et al. Bioconjugate Chem. 2009, 20, 6, 1242), which is problematic for large-scale manufacturing and production, and may cause systemic side effects caused by aggregation. So far, the U.S. FDA has only approved three water-soluble camptothecin analogs: topotecan, irinotecan and belotecan for cancer treatment (Palakurthi, S., Expert Opin Drug Deliv. 2015, 12 (12), 1911). Most of the camptothecin payloads used for ADC development so far have low solubility, which further limits the ratio of drug to antibody and leads to low efficacy.
[0008] The present application provides a series of ligand-drug conjugates of camptothecin analogs. Summary of the invention
[0009] The present application provides conjugates of camptothecin analogs connected to cell-binding molecules, camptothecin analogs-linker compounds and camptothecin analogs, methods for preparing them and methods for using them, and intermediates that can be used to prepare them. The camptothecin analog conjugates of the present application are stable in circulation, and once the metabolites of free camptothecin analogs or camptothecin analogs-linker compounds are released from the conjugates near or in disordered cells, high cytotoxicity is provided.
[0010] In general: These compounds or pharmaceutically acceptable salts or solvates thereof have Formula I:
[0011] Aspect 1: The present application provides a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, wherein the ligand-drug conjugate comprises a drug unit D of formula I 1 : in: X is absent or selected from -O-, -S-, -S(O2)-, -S(O)-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C8 cycloalkyl, C1-C8 alkyl, C1-C8 alkoxy, R 5-(C1-C8 alkylene)-, amino, (C1-C8 alkyl)NHC(O)O-, (C3-C8 cycloalkyl)NHC(O)O-, (C1-C8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, (C1-C8 alkyl)C(O)O-, (C1-C8 alkyl)C(O)NH-; wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, C1-C8 alkoxy, each "C3-C8 cycloalkyl" and each "C1-C8 alkyl" are independently optionally substituted by one to four R 6 replace; R 3 and R 4 Independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl, amino; wherein C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R6; R 5 is selected from C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl; wherein C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C8 alkyl, C3-C8 cycloalkyl, aryl, heteroaryl; and a line with a dashed line therein represents a single bond or a double bond; n is 0 or 1.
[0012] In some embodiments of aspect 1, including formula (I), wherein: X is selected from -O-, -S-, -S(O2)-, -S(O)-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C6 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, R 5 -(C1-C3 alkylene)-, amino; wherein C1-C6 alkoxy, C3-C6 cycloalkyl and C1-C6 alkyl are independently optionally substituted by one to four R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl; wherein C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 5 is C1-C6 alkoxy or C3-C6 cycloalkyl; wherein C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C3 alkyl, C3-C6 cycloalkyl; and a line with a dashed line therein represents a single bond or a double bond; n is 0 or 1.
[0013] In some embodiments of aspect 1, wherein D 1 It is represented by formula II: Where: X is -O- or -S-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1b , R 2 , R 3 , R 4 and dashed lines are as defined in Formula (I) and any of its Examples.
[0014] In some embodiments of aspect 1, including any one of formula (I) and (II) and any embodiments thereof: wherein R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens.
[0015] In some embodiments of aspect 1, including any one of formula (I) and (II) and any embodiments thereof: wherein the dashed line represents a double bond.
[0016] In some embodiments of aspect 1, including any one of formula (I) and (II) and any embodiments thereof: wherein the dashed line represents a single bond.
[0017] In some embodiments of aspect 1, including any one of formula (I) and (II) and any embodiments thereof: wherein R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens; dashed lines represent double bonds.
[0018] In some embodiments of aspect 1, D 1 Including but not limited to:
[0019] In some embodiments of aspect 1, the provided ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is according to formula (III): in: T is the targeting or binding ligand; L is a releasable linker; D 1 As defined in aspect 1, including any one of formula (I) and (II) and any embodiments thereof; and m is an integer or decimal between 1 and 10.
[0020] In some embodiments of aspect 1, in the ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to the present disclosure, including any one of formula (I), (II) and (III) and any embodiment thereof, the linker unit L is -L 1 -L 2 -L 3 -L 4 -,in: L 1 Freedom to choose -CH2-C(O)-NR 7 -WC(O)-, -CH(COOH)-C(O)-NR 7 -WC(O)- and -C(O)-WC(O)-; wherein W and W 1independently selected from C1-C8 alkylene, -(C1-C8 alkylene)-cycloalkylene, arylene, -arylene-(C1-C8 alkylene)-, heteroarylene and linear heteroalkylene, wherein the linear heteroalkylene comprises 1 to 8 carbon atoms, and 1 to 6 heteroatoms selected from N, O and S, SO, SO2, and wherein the -(C1-C8 alkylene)-cycloalkylene, linear heteroalkylene, arylene and heteroarylene are each independently optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein q is an integer selected from 1 to 6; wherein Z is selected from the group consisting of C1-C6 alkylene, C1-C6 alkenylene, C1-C6 alkynylene, arylene and heteroarylene; wherein Y is selected from the group consisting of -O-, -S-, -C(R 7 )(R 8 )- and heteroarylene group; wherein the above provided L 1 The left side of each of the groups is connected to T; L 2 Choose Free-NR 8 (CH2CH2O) p 1 CH2CH2C(O)-、-NR 8 (CH2CH2O) p 1 CH2CH2-、-NR 8 (CH2CH2O) p 1 CH2C(O)-、-S(CH2) p 1 C(O)-、-NR 8 -(CH2) p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O) p 1 CH2C(O), -NR 8 -(CH2) p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O) p 1 CH2CH2NHC(O)CH2OCH2C(O), -NR 8 (CH2CH2O) p 1 CH2CH2NHC(O)CH2OCH2C(O) and chemical bonds, where p 1 is an integer selected from 1 to 20; wherein p 2is an integer selected from 1 to 3; wherein the L provided above 2 The left side of each of the groups is attached to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the L provided above 3 The left side of each group is connected to L 2 ; L 4 Choose Free-NR 9 (CR 10 R 11 ) t -、 and a chemical bond, wherein t is an integer selected from 1 to 6; wherein, in the presence of L 4 In the case of the above provided L 4 The left side of each of the groups is attached to L 3 on the right side, and L 4 The right side of each of the groups is attached to D 1 ; R 7 , R 8 , R 9 and R 12 are each independently selected from hydrogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; R 10 , R 11 , R 13 and R 14 are each independently selected from hydrogen, halogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl; and R 15 Selected from -CH2CH2SO2CH3 and -CH2CH2N(CH3)2.
[0021] In some embodiments of aspect 1, in the ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to the present disclosure, including any one of formula (I), (II) and (III) and any embodiment thereof, the linker unit L 1 Freedom to choose and -CH(COOH)-C(O)-NH-C6H4-(CH2)s 3 -C(O)- (where the left side of the group is connected to T), where s 1 is an integer selected from 2 to 8; s 2 is an integer selected from 1 to 3; s 3An integer selected from 1 to 8; q is an integer selected from 1 to 3; and Z is selected from the group consisting of C1-C6 alkylene, C1-C6 alkenylene and C1-C6 alkynylene.
[0022] In some embodiments of aspect 1, in the ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to the present application, including any one of formula (I), (II) and (III) and any embodiment thereof, the linker unit L 2 Choose Free-NR 8 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 8 (CH2CH2O) p 1 CH2C(O)-、-NR 8 -(CH2)p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O)p 1 CH2C(O) and chemical bonds; R 8 is selected from the group consisting of hydrogen, alkyl, halogenated alkyl, deuterated alkyl and hydroxyalkyl; 1 is an integer selected from 6 to 12; p 2 is an integer selected from 1 to 3; wherein the L provided above 2 The left side of each of the groups is attached to L 1 .
[0023] In some embodiments of aspect 1, in the ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to the present disclosure, including any one of formula (I), (II) and (III) and any embodiment thereof, the linker unit L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are selected from phenylalanine (F), glycine (G), valine (V), lysine (K), citrulline, serine (S), alanine (a), glutamic acid (E) and aspartic acid (D). 3 is a peptide residue consisting of 1, 2 or more phenylalanine and glycine. In certain embodiments, L 3 is a peptide residue consisting of 4 amino acids. 3 is a peptide residue GGFG or VA; wherein the L provided above 3 The left side of each of the groups is attached to L 2 .
[0024] In some embodiments of aspect 1, in the ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to the present disclosure, including any one of formula (I), (II) and (III) and any embodiment thereof, the linker unit L 4 Yes - NR 9 (CR 10 R 11 ) t -、 Chemical bond; R 9 , R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from hydrogen and alkyl; R 15 is selected from -CH2CH2SO2CH3 and -CH2CH2N(CH3)2; t is 1 or 2; wherein in the presence of L 4 In the case of the above provided L 4 The left side of each of the groups is attached to L 3 on the right side, and L 4 The right side of each group is attached to D 1 In certain embodiments, L 4 It's a chemical bond.
[0025] In some embodiments of aspect 1, in the ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to the present disclosure, including any one of formula (I), (II) and (III) and any embodiment thereof, the linker unit L is -L 1 -L 2 -L 3 -,in: L 1 yes where s 1 is an integer selected from 2 to 8; s 2 is an integer selected from 1 to 3; and q is an integer selected from 1 to 3; L 2 Choose Free-NR 8 (CH2CH2O) p 1 CH2CH2C(O)-、-NR 8 (CH2CH2O) p 1 CH2C(O)-、-NR 8 -(CH2) p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O) p 1CH2C(O) and chemical bonds, where R 8 is selected from the group consisting of hydrogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl; 1 is an integer selected from 6 to 12; p 2 is an integer selected from 1 to 3; wherein the L provided above 2 The left side of each of the groups is attached to L 1 ; L 3 is a peptide residue GGFG or VA; wherein the L provided above 3 The left side of each group is connected to L 2 ; And each L provided above 1 The left side of the group is connected to the ligand, and the individual L provided above 3 The right side of the group is connected to D 1 .
[0026] In some embodiments of aspect 1, in the ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to the present disclosure, including any one of formula (I), (II) and (III) and any embodiments thereof, the linker unit L includes but is not limited to:
[0027] In some embodiments of aspect 1, the ligand-drug conjugates include but are not limited to: or a pharmaceutically acceptable salt or solvate thereof; wherein T and m are as defined in formula (III) and any embodiments thereof, and wherein further embodiments of T are provided below.
[0028] In some embodiments of aspect 1, a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is provided, wherein: T is a targeting antibody or ligand that binds to an antigen; wherein the antibody is selected from a chimeric antibody, a humanized antibody and a human antibody; alternatively, wherein T is a monoclonal antibody.
[0029] In some embodiments of aspect 1, a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is provided, wherein: T is selected from anti-Her2 (ErbB2) antibody, anti-EGFR antibody, anti-B7H3 antibody, anti-c-MET antibody, anti-Her3 (ErbB3) antibody, anti-Her4 (ErbB4) antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-D33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MUC1 antibody, anti-Lewis antibody Y antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-integrin antibody, anti-PSMA antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody, anti-mesothelin antibody, anti-ROR1 antibody, and antigen-binding fragments.
[0030] In some embodiments of aspect 1, a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is provided, wherein: T is selected from Trastuzumab, Pertuzumab, Nimotuzumab, Enoblituzumab, Emibetuzumab, Inotuzumab, Pinatuzumab, Brentuximab, Gemtuzumab, Bivatuzumab, Lorvotuzumab, cBR96, Glembatumumab, or a fragment that binds to an antigen.
[0031] In some embodiments of aspect 1, a ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof is provided, wherein: T is trastuzumab, m is an integer or decimal between 1-10; optionally m is an integer or decimal between 3-8.
[0032] Aspect 2: In some other embodiments of the present application, a compound or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof is provided, wherein the compound is of formula (IV): LD 1 (IV) Where: D 1 Represented by formula I: in: X is absent or selected from -O-, -S-, -S(O2)-, -S(O)-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C8 cycloalkyl, C1-C8 alkyl, C1-C8 alkoxy, R 5 -(C1-C8 alkylene)-, amino, (C1-C8 alkyl)NHC(O)O-, (C3-C8 cycloalkyl)NHC(O)O-, (C1-C8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, (C1-C8 alkyl)C(O)O-, (C1-C8 alkyl)C(O)NH-; wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, C1-C8 alkoxy, each "C3-C8 cycloalkyl" and each "C1-C8 alkyl" are independently optionally substituted by 1-4 R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C8 alkyl, C1-C8-alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl, amino; wherein C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 5 is selected from C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl; wherein C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C8 alkyl, C3-C8 cycloalkyl, aryl, heteroaryl; and a line with a dashed line therein represents a single bond or a double bond; n is 0 or 1; and where L is L 1a -L 2 -L 3 -L 4 -, L 1a Selected from and COOH-WC(O)-; where W and W 1 independently selected from the group consisting of C1-C8 alkylene, -(C1-C8 alkylene)-cycloalkylene-, arylene, -arylene-(C1-C8 alkylene)-, heteroarylene and linear heteroalkylene, wherein the linear heteroalkylene contains 1 to 8 carbon atoms, and 1 to 6 heteroatoms selected from N, O and S, SO, SO2, and wherein the -(C1-C8 alkylene)-cycloalkylene-, linear heteroalkylene, arylene and heteroarylene are each independently optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein q is an integer selected from 1-6; wherein Z is selected from the group consisting of C1-C6 alkylene, C1-C6 alkenylene, C1-C6 alkynylene, arylene and heteroarylene; wherein Y is selected from -O-, -S-, -C(R 7 )(R 8 )- and heteroarylene group; L 2 Choose Free-NR 8 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 8 (CH2CH2O)p 1 CH2CH2-、-NR 8 (CH2CH2O) p 1 CH2C(O)-、-S(CH2)p 1 C(O)-、-NR 8 -(CH2)p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O)p 1 CH2C(O), -NR 8 -(CH2)p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O)p 1 CH2CH2NHC(O)CH2OCH2C(O), -NR 8 (CH2CH2O)p 1 CH2CH2NHC(O)CH2OCH2C(O) and chemical bonds, where p1 is an integer selected from 1 to 20; wherein p 2 is an integer selected from 1 to 3; wherein the L provided above 2 The left side of each of the groups is attached to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the L provided above 3 The left side of each group is connected to L 2 ; L 4 Choose Free-NR 9 (CR 10 R 11 ) t -、 and a group consisting of a chemical bond, wherein t is an integer selected from 1-6; wherein the L provided above 4 The left side of each group is attached to L 3 on the right side, and each L 4 The right side of each group is attached to D 1 ; R 7 , R 8 , R 9 and R 12 are each independently selected from the group consisting of hydrogen, alkyl, halogenated alkyl, deuterated alkyl, and hydroxyalkyl; R 10 , R 11 , R 13 and R 14 are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; and R 15 Selected from -CH2CH2SO2CH3 and -CH2CH2N(CH3)2.
[0033] In some embodiments of aspect 2, wherein: X is selected from -O-, -S-, S(O2)-, -S(O)-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1bSelected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C6 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, R 5 -(C1-C3 alkylene)-, amino; wherein C1-C6 alkoxy, C3-C6 cycloalkyl and C1-C6 alkyl are independently optionally substituted by one to four R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6-alkoxy, C3-C6 cycloalkyl; wherein C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 5 is C1-C6 alkoxy or C3-C6 cycloalkyl; wherein C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C3 alkyl, C3-C6 cycloalkyl; and a line with a dashed line therein represents a single bond or a double bond; n is 1.
[0034] In some embodiments of aspect 2, wherein D 1 It is represented by formula II: Where: X is -O- or -S-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1b , R 2 , R 3 , R 4 and dashed lines are as defined in formula (I) and (IV) and any examples thereof.
[0035] In some embodiments of aspect 2, including any one of formula (I), (II) and (IV) and any embodiments thereof: wherein R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens.
[0036] In some embodiments of aspect 2, including any one of formula (I), (II) and (IV) and any embodiments thereof: wherein the dashed line represents a double bond.
[0037] In some embodiments of aspect 2, including any one of formula (I), (II) and (IV) and any embodiments thereof: wherein R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens; dashed lines represent double bonds.
[0038] In some embodiments of aspect 2, D 1 Including but not limited to:
[0039] In some embodiments of aspect 2, in the compound or pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof according to the present application, including any one of formula (IV) and any embodiment thereof, the linker unit L 1a Selected from where s 1 is an integer selected from 2 to 8; s 2 is an integer selected from 1 to 3; q is an integer selected from 1 to 33; and Z is selected from the group consisting of C1-C6 alkylene, C1-C6 alkenylene and C1-C6 alkynylene.
[0040] In some embodiments of aspect 2, in the compounds according to the present application or their pharmaceutically acceptable salts, solvates, tautomers, mesomers, racemates, enantiomers, diastereomers or combinations thereof, including any one of formula (IV) and any of its embodiments, the linker unit L 2 Choose Free-NR 8 (CH2CH2O) p 1CH2CH2C(O)-、NR 8 (CH2CH2O) p 1 CH2C(O)-、-NR 8 -(CH2) p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O) p 1 CH2C(O) and chemical bonds; R 8 is selected from the group consisting of hydrogen, alkyl, halogenated alkyl, deuterated alkyl and hydroxyalkyl; 1 is an integer selected from 6 to 12; p 2 is an integer selected from 1 to 3; wherein the L provided above 2 The left side of each of the groups is attached to L 1 .
[0041] In some embodiments of aspect 2, in the compound or pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof according to the present application, including any one of formula (IV) and any embodiment thereof, the linker unit L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are selected from phenylalanine (F), glycine (G), valine (V), lysine (K), citrulline, serine (S), alanine (A), glutamic acid (E) and aspartic acid (D). 3 is a peptide residue consisting of 1, 2 or more phenylalanine and glycine. In certain embodiments, L 3 is a peptide residue consisting of 4 amino acids. 3 is a peptide residue GGFG or VA; wherein the L provided above 3 The left side of each of the groups is attached to L 2 .
[0042] In some embodiments of aspect 2, in the compound or pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof according to the present application, including any one of formula (IV) and any embodiment thereof, the linker unit L 4 Yes - NR 9 (CR 10 R 11 ) t -、 Chemical bond; R 9 , R 10 , R 11 , R 12, R 13 and R 14 are each independently selected from hydrogen and alkyl; R 15 is selected from -CH2CH2SO2CH3 and -CH2CH2N(CH3)2; t is 1 or 2; wherein in the presence of L 4 In the case of the above provided L 4 The left side of each of the groups is attached to L 3 on the right side, and L 4 The right side of each group is attached to D 1 In certain embodiments, L 4 It's a chemical bond.
[0043] In some embodiments of aspect 2, in the compounds or pharmaceutically acceptable salts, solvates, tautomers, mesomers, racemates, enantiomers, diastereomers or combinations thereof according to the present disclosure, including any one of formula (IV) and any of its embodiments, the linker unit L is L 1a -L 2 -L 3 -, where: L 1a yes where s 1 is an integer selected from 2 to 8; s 2 is an integer selected from 1 to 3; and q is an integer selected from 1 to 3; L 2 Choose Free-NR 8 (CH2CH2O) p 1 CH2CH2C(O)-、-NR 8 (CH2CH2O) p 1 CH2C(O)-、-NR 8 -(CH2)p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O)p 1 CH2C(O) and chemical bonds, where R 8 is selected from the group consisting of hydrogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl; 1 is an integer selected from 6 to 12; p 2 is an integer selected from 1 to 3; wherein the L provided above 2 The left side of each of the groups is attached to L 1 ; L 3 is a peptide residue GGFG or VA; wherein the L provided above 3 The left side of each group is connected to L 2 ; And wherein the above provided L 3 The right side of each group is connected to D 1 .
[0044] In some embodiments of aspect 2, in the compounds or pharmaceutically acceptable salts, solvates, tautomers, mesomers, racemates, enantiomers, diastereomers or combinations thereof according to the present application, including any one of formula (IV) and any of its embodiments, the linker unit L includes but is not limited to:
[0045] In some embodiments of aspect 2, the compound includes but is not limited to: or a pharmaceutically acceptable salt, solvate, tautomer, mesoform, racemate, enantiomer, diastereomer or a combination thereof.
[0046] Aspect 3: In some embodiments of the present disclosure, provided are compounds or pharmaceutically acceptable salts, solvates, tautomers, mesomers, racemates, enantiomers, diastereomers or combinations thereof, wherein the compound of formula (V): in X is absent or selected from -O-, -S-, -S(O2)-, -S(O)-; R 1 Yes-NH-R 1b -OH, hydroxyl, amino; optionally, R 1 is a hydroxyl or amino group; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C8 cycloalkyl, C1-C8 alkyl, C1-C8 alkoxy, R 5 -(C1-C8 alkylene)-, amino, (C1-C8 alkyl)NHC(O)O-, (C3-C8 cycloalkyl)NHC(O)O-, (C1-C8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, (C1-C8 alkyl)C(O)O-, (C1-C8 alkyl)C(O)NH-; wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, C1-C8 alkoxy, each "C3-C8 cycloalkyl" and each "C1-C8 alkyl" are independently optionally substituted by one to four R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl, amino; wherein C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 5 is selected from C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl; wherein C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C8 alkyl, C3-C8 cycloalkyl, aryl, heteroaryl; and a line with a dashed line therein represents a single bond or a double bond; n is 0 or 1; Provided that when X is -O- or -S-, and the dashed line represents a single bond, then R 2 , R 3 and R 4 Not all H and not amino.
[0047] In some embodiments of aspect 3, provided are compounds or pharmaceutically acceptable salts, solvates, tautomers, mesomers, racemates, enantiomers, diastereomers or combinations thereof, wherein the compound of formula (VI): Where: R 1 , R 2 , R 3 , R 4 , X and n are as defined in formula (V) and any of its embodiments.
[0048] In some embodiments of aspect 3, provided are compounds or pharmaceutically acceptable salts, solvates, tautomers, mesomers, racemates, enantiomers, diastereomers or combinations thereof, wherein the compound of formula (VII): in: X is selected from -O-, -S-, -S(O2)-, -S(O)-; R 1 Yes-NH-R 1b -OH, hydroxyl, amino; optionally, R 1 is a hydroxyl or amino group; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C6 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, R 5 -(C1-C3 alkylene)-, amino; wherein C1-C6 alkoxy, C3-C6 cycloalkyl and C1-C6 alkyl are independently optionally substituted by one to four R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl; wherein C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 5 is C1-C6 alkoxy or C3-C6 cycloalkyl; wherein C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C3 alkyl, C3-C6 cycloalkyl.
[0049] In some embodiments of aspect 3, in the compounds or pharmaceutically acceptable salts, solvates, tautomers, mesomers, racemates, enantiomers, diastereomers or combinations thereof according to the present disclosure, including any one of formula (V), (VI) and (VII) and any embodiments thereof, wherein X is -O- or -S-.
[0050] In some embodiments of aspect 3, in the compounds or pharmaceutically acceptable salts, solvates, tautomers, mesomers, racemates, enantiomers, diastereomers or combinations thereof according to the present disclosure, including any one of formula (V), (VI) and (VII) and any embodiments thereof, wherein R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens.
[0051] In some embodiments of aspect 3, in the compounds or pharmaceutically acceptable salts, solvates, tautomers, mesomers, racemates, enantiomers, diastereomers or combinations thereof according to the present application, including any one of formula (V), (VI) and (VII) and any embodiments thereof, wherein: X is S-; R 1 It is NH-R 1b -OH or amino; optionally, R 1 It is amino; R 1b -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)-, and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens.
[0052] In some embodiments of aspect 3, the compound includes but is not limited to: or a pharmaceutically acceptable salt, solvate, tautomer, mesoform, racemate, enantiomer, diastereomer or a combination thereof.
[0053] In another embodiment, the cell-surface binding molecule T can be any type currently known, or become a known cell binding ligand, such as a peptide and a non-peptide. Generally, the cell-binding molecule T is an antibody; a single-chain antibody; an antibody fragment that binds to the target cell; a monoclonal antibody; a single-chain monoclonal antibody; or a monoclonal antibody fragment that binds to a target cell; a chimeric antibody; a chimeric antibody fragment that binds to the target cell; a domain antibody; a domain antibody fragment that binds to the target cell; adnectins that mimic antibodies, DARPins; lymphokines; hormones; vitamins; growth factors; colony stimulating factors; nutrient transport molecules (transferrin), binding peptides, proteins, antibodies, small molecules attached to albumin, polymers, dendrimers, liposomes, nanoparticles, vesicles, (virus) capsids. In certain embodiments, the binding molecule T is a monoclonal antibody.
[0054] The present application also provides compounds of formula (I), (II), (III), (IV), (V), (VI) and (VII) and any embodiments thereof, including compounds defined in Aspect 1, Aspect 2 and Aspect 3, or pharmaceutically acceptable salts or solvates thereof, wherein the compounds are tautomers, mesomers, racemates, enantiomers, diastereomers or mixtures thereof.
[0055] The present application also provides a ligand-drug conjugate, wherein the compound as defined in aspect 3 or a pharmaceutically acceptable salt, solvate, tautomer, mesoform, racemate, enantiomer, diastereomer or a combination thereof is used as a toxin.
[0056] Another aspect of the present application provides a method for preparing a ligand-drug conjugate of formula (I), (II) and (III) and any embodiment thereof, or a pharmaceutically acceptable salt or solvate thereof, and optionally a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof.
[0057] Another aspect of the present application further relates to a pharmaceutical composition comprising a therapeutically effective amount of 1) a ligand-drug conjugate or compound according to the present application or a pharmaceutically acceptable salt or solvate thereof and optionally a tautomer, mesomer, racemate, enantiomer, diastereomer or a mixture thereof, and 2) one or more pharmaceutically acceptable carriers, diluents or excipients.
[0058] Another aspect of the present application also relates to 1) the use of the ligand-drug conjugate or compound of the present application, or a pharmaceutically acceptable salt or solvate thereof, and optionally tautomers, mesomers, racemates, enantiomers, diastereomers or mixtures thereof, or 2) the use of the pharmaceutical composition comprising the same drug according to the present application in the preparation of a drug for treating or preventing tumors, and optionally the tumor is a cancer associated with the expression of HER2, HER3 or EGFR.
[0059] Another aspect of the present application also relates to: 1) the use of a ligand-drug conjugate or compound, or a pharmaceutically acceptable salt or solvate thereof, and optional tautomers, mesomers, racemates, enantiomers, diastereomers or mixtures thereof, or 2) the use of a pharmaceutical composition comprising the same drug according to the present disclosure in the preparation of a medicament for treating or preventing tumors. In certain embodiments, the cancer is selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer and lymphoma (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, relapsed anaplastic large cell lymphoma).
[0060] The active compound can be formulated into a form suitable for administration by an appropriate route, and the active compound can be in a unit dose form in advance, or in a form that the patient can self-administer by a single dose. The unit dose form of the compound or composition of the present application can be tablets, capsules, cachets, bottle portions, powders, granules, lozenges (tablets), suppositories, reconstituted powders or liquid preparations.
[0061] The dosage of the compound or composition in the treatment method of the present application will generally vary depending on the severity of the disease, the patient's weight and the relative efficacy of the compound. However, as a general guide, a suitable unit dosage may be 0.1 to 1000 mg.
[0062] In addition to the active compound, the pharmaceutical composition of the present application may also contain one or more auxiliary agents, including filter (diluent), binder, wetting agent, disintegrant, excipient, etc. Depending on the administration method, the composition may contain 0.1 to 99 wt% of the active compound.
[0063] The pharmaceutical composition containing active ingredients can be in a form suitable for oral administration, such as tablets, lozenges, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs. Oral compositions can be prepared according to any known method for preparing pharmaceutical compositions in the art. Such compositions can include adhesives, fillers, lubricants, disintegrants or pharmaceutically acceptable wetting agents, etc. Such compositions can also include one or more components selected from sweeteners, flavorings, coloring agents and preservatives to provide a pleasant and palatable pharmaceutical preparation.
[0064] Aqueous suspensions include the active ingredient in admixture with excipients suitable for the preparation of aqueous suspensions. Aqueous suspensions may also contain one or more preservatives, one or more coloring agents, one or more flavoring agents and one or more sweetening agents.
[0065] Oil suspensions can be prepared by suspending the active ingredient in a vegetable oil. Oil suspensions may include a thickener. The above-mentioned sweeteners and flavoring agents may be added to provide a palatable preparation.
[0066] The pharmaceutical composition of the present application may also be in the form of an oil-in-water emulsion.
[0067] The pharmaceutical composition can be in the form of a sterile injectable aqueous solution. Acceptable carriers or solvents that can be used are water, Ringer's solution or isotonic sodium chloride solution. The sterile injectable preparation can be a sterile injectable oil-in-water microemulsion, in which the active ingredient is dissolved in the oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol and treated to form a microemulsion. The injectable solution or microemulsion can be introduced into the patient's blood by local intravenous bolus injection. Alternatively, the solution and microemulsion are preferably administered in a manner that maintains a constant circulating concentration of the compound of the present disclosure. In order to maintain this constant concentration, a continuous intravenous delivery device can be used. Deltec CADD-PLUS TM The 5400 IV Pump is an example of such a device.
[0068] The pharmaceutical composition can be in the form of a sterile injectable aqueous or oily suspension for intramuscular and subcutaneous administration. According to known techniques, this suspension can be prepared with a suitable dispersant or wetting agent and a suspending agent as described above. Sterile injectable preparations can also be sterile injectable solutions or suspensions prepared in nontoxic parenteral acceptable diluents or solvents. In addition, sterile fixed oils can be easily used as solvents or suspension media.
[0069] The compounds of the present application can be administered in the form of suppositories for rectal administration. These pharmaceutical compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid in the rectum, thereby melting in the rectum to release the drug. These materials include cocoa butter, glycerin gelatin, hydrogenated vegetable oils, polyethylene glycols of various molecular weights and mixtures of their fatty acid esters.
[0070] It is well known to those skilled in the art that the dosage of a drug depends on a variety of factors, including but not limited to the following factors: the activity of a particular compound, the age of the patient, the weight of the patient, the overall health of the patient, the behavior of the patient, the diet of the patient, the administration time, the administration route, the excretion rate, the drug combination, etc. In addition, the optimal treatment, such as the treatment mode, the daily dose of the compound of formula (I) or the type of its pharmaceutically acceptable salt, can be verified according to traditional treatment regimens. DETAILED DESCRIPTION
[0071] Unless otherwise specified, all technical and scientific terms used herein are in accordance with the common understanding of ordinary technicians in the field to which this application belongs. Although any methods and materials similar or equivalent to the methods and materials described herein can be used in the practice or testing of this application, preferred methods and materials are described herein. When describing and interpreting this application, the following terms are used according to the following definitions.
[0072] Unless otherwise stated, the terms used in the specification and claims have the following meanings.
[0073] As used herein, "A" and "an" mean one or more unless the context clearly dictates otherwise.
[0074] "Ligand" refers to a compound that can recognize and bind to an antigen or receptor associated with a target cell. The role of the ligand is to deliver the drug to a target cell population that binds to the ligand. Such ligands include, but are not limited to, protein hormones, lectins, growth factors, antibodies, peptides, or other molecules that can bind to cells. In one embodiment of the present application, for trastuzumab, the ligand is represented by T. The ligand can form a bond with the linker through a heteroatom on the ligand. In certain embodiments, the ligand is an antibody or an antigen-binding fragment thereof. The antibody is selected from the group consisting of a chimeric antibody, a humanized antibody, a fully humanized antibody, or a murine antibody. In certain embodiments, the ligand is a monoclonal antibody.
[0075] The term "drug" refers to a cytotoxic drug provided herein, which is a chemical molecule that can strongly destroy the normal growth of tumor cells. In principle, all cytotoxic drugs can kill tumor cells at sufficiently high concentrations. However, they may cause apoptosis of normal cells, resulting in serious side effects, or even kill normal cells while killing tumor cells due to lack of specificity.
[0076] The term "linker", "linker unit", "linking fragment" or "linking unit" refers to a chemical structure fragment or bond that is connected to a ligand at one end and to a drug at the other end. 1 To L 4 Indicates that L 1 The end is connected to the ligand, L 4 The end is connected to the drug.
[0077] Linkers, including extension units, spacer units, and amino acid units, can be synthesized by methods known in the art, such as those described in US2005-0238649A1. Linkers can be "cleavable linkers" or "releasable linkers" that facilitate the release of drugs in cells. For example, acid-labile linkers (e.g., hydrazones), protease-sensitive (e.g., peptidase-sensitive) linkers, photo-labile linkers, dimethyl linkers, disulfide bond-containing linkers (Chari et al., Cancer Research 52: 127-131 (1992); US Pat. No. 5,208,020) can be used.
[0078] The term "ligand-drug conjugate" refers to a bioactive drug connected to a ligand provided herein via a stable linker. In the present application, a "ligand-drug conjugate" is optionally an antibody-drug conjugate (ADC), which means that a toxic drug is connected to a monoclonal antibody or antibody fragment having biological activity via a stable linker.
[0079] The three letter codes and one letter codes for amino acids used in this application are as described in J. Biol. Chem, 243, p3558 (1968).
[0080] The term "antibody" refers to immunoglobulins, a tetrapeptide chain structure linked together by interchain disulfide bonds between two identical heavy chains and two identical light chains. Different immunoglobulin heavy chain constant regions have different amino acid compositions and sequences, and therefore have different antigenicity. Therefore, immunoglobulins can be divided into five types, or immunoglobulin isotypes, namely IgM, IgD, IgG, IgA and IgE, with corresponding heavy chains |i, |y, |a and |e, respectively. Depending on the amino acid composition of the hinge region and the number and position of the heavy chain disulfide bonds, the same type of Ig can be further divided into different subtypes, for example, IgG can be divided into IgGl, IgG2, IgG3 and IgG4. Light chains can be divided into K chains or Lambda chains depending on the constant region. Each of the five types of Ig can have K or Lambda chains. The antibodies described in the present disclosure may be selected as specific antibodies against cell surface antigens on target cells, non-limiting examples of which are one or more of the following antibodies: anti-Her2 (ErbB2) antibody, anti-EGFR antibody, anti-B7H3 antibody, anti-c-MET antibody, anti-Her3 (ErbB3) antibody, anti-Her4 (ErbB4) antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-D33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MUC1 antibody, anti-Lewis antibody Y antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-integrin antibody, anti-PSMA antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody or anti-mesothelin antibody, and optionally trastuzumab (trade name Herceptin), pertuzumab (also known as 2C4, trade name Peijeta), nimotuzumab (trade name Taixinshe ng), Enoblituzumab, Emibetuzumab, Inetuzumab, Pinatuzumab, Brentuximab, Gemtuzumab, Bivatuzumab, Lorvotuzumab, cBR96, and Glembatumumab.
[0081] The approximately 110 amino acid sequences adjacent to the N-terminus of the heavy or light chain of an antibody are highly variable and are called the variable region (Fv region); the remaining amino acid sequences adjacent to the C-terminus are relatively stable and are called the constant region. The variable region includes three hypervariable regions (HVRs) and four relatively conserved framework regions (FRs). The three hypervariable regions that determine the specificity of the antibody are also called complementary determining regions (CDRs). Each light chain variable region (LCVR) or each heavy chain variable region (HCVR) consists of three CDR regions and four FR regions, in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; and the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3.
[0082] The antibodies of the present application include murine antibodies, chimeric antibodies, humanized antibodies and fully humanized antibodies, preferably humanized antibodies and fully humanized antibodies.
[0083] The term "murine antibody" in this application refers to an antibody prepared by murines according to the knowledge and skills in the art. In the preparation process, a subject is injected with a specific antigen, and then a hybridoma expressing an antibody with the desired sequence or functional characteristics is isolated.
[0084] The term "chimeric antibody" is an antibody obtained by fusing the variable region of a murine antibody with the constant region of a human antibody, and the chimeric antibody can reduce the immune response induced by the murine antibody. In order to establish a chimeric antibody, a hybridoma secreting a murine-specific monoclonal antibody is established, and the variable region gene is cloned from the murine hybridoma cell; then the constant region gene of the human antibody is cloned as needed; the human constant region gene is connected to the murine variable region gene to form a chimeric gene, which is then inserted into an expression vector; finally, the chimeric antibody molecule is expressed in a eukaryotic or prokaryotic system.
[0085] The term "humanized antibody" is also referred to as CDR-transplanted antibody, which refers to antibodies produced by transplanting murine CDR sequences into human antibody variable region frameworks, i.e. antibodies produced in different types of human germline antibody framework sequences. Humanized antibodies can overcome heterologous reactions induced by a large number of murine protein components carried by chimeric antibodies. Such framework sequences can be obtained from public DNA databases or published references covering germline antibody gene sequences. For example, germline DNA sequences of human heavy and light chain-variable region genes can be found in the "VBase" human germline sequence database (available on the World Wide Web at www.mrccpe.com.ac.uk / VBase) and Kabat, EA, et al. 1991Sequences of Proteins of Immunological Interest, 5th Ed. In order to avoid the reduction in activity caused by reduced immunogenicity, the framework sequences in the human antibody variable regions can be subjected to minimal reverse mutations or back mutations to maintain activity. The humanized antibodies of the present application also include humanized antibodies, which are subjected to CDR affinity maturation thereon by phage display. References further describing methods involving humanized murine antibodies include, for example, Queen et al., Proc., Natl. Acad. Sci. USA, 88, 2869, 1991, Winter and colleagues' method [Jones et al., Nature, 321, 522 (1986), Riechmann et al., Nature, 332, 323-327 (1988), and Verhoeyen et al., Science, 239, 1534 (1988)].
[0086] The term "fully humanized antibody" is also called "fully humanized monoclonal antibody", in which the variable region and constant region of the antibody are both from humans, eliminating immunogenicity and side effects. The development of monoclonal antibodies has gone through four stages, namely: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies and fully humanized antibodies. The antibody of the present application is a fully humanized monoclonal antibody. The relevant technologies for the preparation of fully humanized antibodies mainly include human hybridoma technology, EBV transformed B lymphocyte technology, phage display technology, transgenic mouse antibody preparation technology, single B cell antibody preparation, etc.
[0087] The term "antigen binding fragment" refers to one or more fragments of an antibody that retains the ability to specifically bind to an antigen. It has been shown that fragments of full-length antibodies can be used to achieve the function of binding to an antigen. Examples of binding fragments in the term "antigen binding fragment" include (i) Fab fragments, which are monovalent fragments consisting of VL, VH, CL and CH1 domains; (ii) F(ab')2 fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bond in the hinge region; (iii) Fd fragments, which consist of VH and CH: domains; (iv) Fv fragments, which consist of the VH and VL domains of a single-armed antibody; (v) a single domain or dAb fragment consisting of a VH domain (Ward et al. (1989) Nature 341: 544-546); and (vi) isolated complementarity determining regions (CDRs) or (vii) a combination of two or more isolated CDRs optionally linked by a synthetic linker. In addition, although the VL domain and VH domain of the Fv fragment are encoded by two independent genes, they can be connected by a synthetic linker using a recombinant method to produce a single protein chain of a monovalent molecule formed by pairing the VL and VH domains (called a single-chain Fv (scFv); for example, see Bird et al. (1988) Science: 242: 423-426 and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85: 5879-5883). Such single-chain antibodies are also included in the term "antigen-binding fragment" of an antibody. Such antibody fragments are obtained using conventional techniques known to those skilled in the art, and functional fragments are screened using the same methods as intact antibodies. Antigen binding sites can be produced by recombinant DNA technology-or by enzymatic or chemical destruction of intact immunoglobulins. The antibodies can be antibodies of different isotypes, such as IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtypes), IgA1, IgA2, IgD, IgE, or IgM antibodies.
[0088] Fab is an antibody fragment obtained by treating an IgG antibody molecule with papain, which cleaves the amino acid residue at position 224 of the H chain. The Fab fragment has a molecular weight of about 50,000 and has antigen-binding activity, in which about half of the N-terminal side of the H chain and the entire L chain are bound together by a disulfide bond.
[0089] The term "CDR" refers to one of the six hypervariable regions within the variable domain of an antibody that primarily contributes to antigen binding. - Kabat EA et al. (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242 provides one of the most commonly used definitions of the six CDRs. As used in this application, the Kabat definition of CDR applies only to CDR1, CDR2 and CDR3 (CDRL1, CDRL2, CDRL3 or L1, L2, L3) of the light chain variable domain, and CDR2 and CDR3 (CDRH2, CDRH3 or H2, H3) of the heavy chain variable domain.
[0090] The term "antibody framework" refers to the portion of a variable domain VL or VH that serves as a scaffold for the antigen binding loops (CDRs) of the variable domain. Essentially, it is a variable domain without CDRs.
[0091] The terms "specific binding", "selective binding", "selectively binds" and "specifically binds" refer to the binding of an antibody to an epitope on a predetermined antigen. -7 M affinity (KD) binding, for example, less than about 10 -8 M, 10 -9 M or 10 -10 M or smaller.
[0092] Methods for preparing and purifying antibodies and antigen-binding fragments are well known in the art, such as Cold Spring Harbor Antibody Technical Guide, Chapters 5-8 and 15. Antigen-binding fragments can also be prepared by conventional methods. The antibodies or antigen-binding fragments of the present application are genetically engineered to add one or more human FR regions to the non-human CDR region. Human FR germline sequences can be compared to the IMGT human antibody variable germline gene databases and MOE software, which is derived from the ImMunoGeneTics (IMGT) website at http: / / imgt.cines.fr or the Journal of Immunoglobulins 20011SBN012441351.
[0093] The term "peptide" refers to a compound fragment between amino acids and proteins, consisting of two or more amino acid molecules connected to each other by peptide bonds. Peptides are structural and functional fragments of proteins. Hormones, enzymes, etc. are basically peptides.
[0094] The term "toxin" refers to any substance that may have a deleterious effect on cell growth or proliferation. The toxin may be a small molecule toxin and its derivatives from bacteria, fungi, plants or animals, including camptothecin derivatives such as exatecan, maytansinoid and its derivatives (CN101573384), such as DM1, DM3, DM4, auristatin F (AF) and its derivatives such as MMAF, MMAE, 3024 (WO 2016 / 12790A1, compound 7), diphtheria toxin, exotoxin, ricin A chain, abrin A chain, modeccin, α-sarcin, Aleuritesfordii toxic protein, Dianthin toxic protein, Phytolaca americana toxic protein, protein)(PAPI, PAPII and PAP-S), Momordica charantia inhibitor, Curcin, crotin, Sapaonaria officinalis inhibitor, Gelonin, mitogellin, restrictocin, phenomycin, enomycin, and trichothecenes.
[0095] The term "chemotherapeutic agent" refers to a compound that can be used to treat tumors. The definition also includes anti-hormonal drugs that modulate, reduce, block or inhibit the effects of hormones that promote cancer growth, which are usually in the form of systemic or total therapy. They can be hormones. Examples of chemotherapeutic drugs include alkylating agents, such as thiotepa; cyclosphamide; alkyl sulfonates, such as busulfan, improsulfan and piposulfan; aziridines, such as benaodopa and uredepa; aziridines and methylamelamines, including altretamine, triethylenemelamine and trimethylolomelamin e); nitrogen mustards, such as chlorambucil and chlornaphazine; melphalan and novembichin; nitrosoureas, such as carmustine and chlorozotocin; antibiotics, such as aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin C), calicheamicin, carabicin, chromomycin, carzinophilin, actinomycin D, daunorubicin, detorubicin, doxorubicin, epirubicin, esorubicin, idarubicin, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin;Streptozocin, tuberculocidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate, 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; pterin analogs such as leucovorin, fenvalerate, fenvalerate, dapoxetine ... analogs, such as fludarabine, 6-mercaptopterin, thiomethopterin, thioguanopterin; pyrimidine analogs, such as ancitabine, datrexate, 6-azuridine, carmofil, doxitluridine, enocitabine, floxuridine; androgen, such as calusterone, dromostanolong propionate, propionate, epitiostanol, aromatase inhibitors (testolactone); antiadrenalines (aminoglutethimide, mitotane, trilostane); folic acid supplements (folate); aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; biasntrene; defbfamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine;Mitoguazone; mitoxantrone; mopidamol; nitracrine; pintostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; razoxane; sizofiran; spirogemanium; tenuazonic acid acid; triaziquone; trichlorrotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; dibromodulcitol; pipobroman; gacytosine; arabinoside; cyclophosphamide de; thiotepa; taxanes such as paclitaxel and docetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide; ifbsfamily; mitomycin C C); mitoxantrone; vincristine; vinorelbine; navelbine; novantrone hydrochloride; teniposide; daunorubicin; aminopterin (xeloda); xeloda; ibandronate; topoisomerase inhibitor RFS2000; difluoromethylomithine; retinoic acid esperamicins;Capecitabine; and any pharmaceutically acceptable salt, acid or derivative of the foregoing. This definition also includes anti-hormonal drugs.
[0096] The carbon atom content of various hydrocarbon-containing molecules is indicated by prefixes representing the minimum and maximum number of carbon atoms in the molecule, i.e., the prefix C i -C j It refers to a molecule of carbon atoms from integer "i" to integer "j" (inclusive of the carbon atoms indicated by these two integers). Thus, for example, C1-C6 alkyl refers to an alkyl group having 1 to 6 carbon atoms (inclusive).
[0097] The term "alkyl" as used in this application refers to a straight or branched saturated hydrocarbon substituent (i.e., a substituent obtained by removing hydrogen from a hydrocarbon group); in one embodiment, one to eight carbon atoms, in another embodiment, one to six carbon atoms, and in another embodiment, one to three carbon atoms. Non-limiting examples of such substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and tert-butyl), pentyl, isopentyl, hexyl, heptyl, octyl, etc. In another embodiment, it contains one to three carbons and consists of methyl, ethyl, n-propyl and isopropyl. The phrase "each 'C1-C8 alkyl' is optionally replaced by one to three R 5 Optionally substituted", which means that each "C1-C8 alkyl" in the list of the group may be replaced by one to three R 5 For example, in the following list, "C1-C8 alkyl, (C1-C8 alkyl)NHC(O)O-, (C1-C8 alkyl)NH-, (C1-C8 alkyl)C(O)O-", each C1-C8 alkyl group may be substituted by one to three R 5 In addition to any groups specifically listed in any embodiment or claim, in some structures, the alkyl group is optionally substituted by 1-3 substituents independently selected from halogen, -C1-C 12 Alkyl (unsubstituted or substituted, in one embodiment with 1, 2 or 3 halogenated), aryl, -OH, -OCl-C 12 Alkyl, -S(O) n C1-C4 alkyl (where n is 0, 1, 2), -C1-C4 alkyl NH2, -NHC1-C4 alkyl, -C(=O)H, C(=O)OR a 、-OC(=O)R b 、OC(=O)NR a R c , OC(=O)(heteroaryl), wherein R a , R c and R dare independently hydrogen or -C1-C4 alkyl, and R b It is an alkyl group.
[0098] The term "alkylene" as used herein refers to a divalent alkyl group as defined herein.
[0099] The term "-alkylene-cycloalkylene-" as used herein refers to an alkylene group, as defined herein, bonded to a cycloalkylene group, as defined herein.
[0100] The term "alkoxy" refers to an -OR group, wherein R is an alkyl group as defined herein (i.e., a substituent obtained from a hydrocarbon alcohol by removing hydrogen from OH); in one embodiment, it contains 1 to 6 carbon atoms. Non-limiting examples of such substituents include methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, sec-butoxy and tert-butoxy), pentoxy, hexoxy, etc. In another embodiment, it has one to three carbons and is composed of methoxy, ethoxy, n-propoxy and isopropoxy. The alkoxy group attached to the alkyl group is referred to as an alkoxyalkyl group. An example of an alkoxyalkyl group is methoxymethyl.
[0101] The term "alkoxyalkyl" as used herein refers to an alkyl group, as defined herein, substituted with an alkoxy group.
[0102] The term "cycloalkyl" refers to a carbocyclic substituent obtained by removing hydrogen from a saturated or partially unsaturated (but not including aromatic rings) carbocyclic molecule, such as a carbocyclic molecule having three to seven carbon atoms. The term "cycloalkyl" includes monocyclic saturated carbocyclic rings. The term "C3-C7 cycloalkyl" refers to radicals of three to seven membered ring systems, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The term "C s -C s "Cycloalkyl" refers to a radical of a three- to six-membered ring system, including cyclopropyl, cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexenyl, and cyclohexyl. The cycloalkyl group may also be bicyclic, polycyclic, endocyclic, or spirocyclic carbocyclic. For example, the term "C3-C 12 "Cycloalkyl" includes monocyclic carbocyclic and bicyclic and spirocyclic cycloalkyl molecules, such as dicyclopentyl, dicyclohexyl, dicycloheptyl, dicyclooctyl, dicycloalkenyl, spiropentyl, spirohexyl, spiroheptyl, spirooctyl and spiroranyl. In addition to any groups specifically listed in any embodiment or claim, in some structures, the cycloalkyl is optionally substituted with 1-3 substituents independently selected from halogen, -C1-C 12 Alkyl (unsubstituted or substituted, in one embodiment with 1, 2 or 3 halogenated), aryl, -OH, -O-C1-C 12 Alkyl, -S(O) nC1-C4 alkyl (where n is 0, 1, 2), -C1-C4 alkyl NH2, -NHC1-C4 alkyl, -C(=O)H, C(=O)OR a 、-OC(=O)R b 、OC(=O)NR a R c , OC(=O)heteroaryl and OC(=O)(heterocyclyl), wherein R a , R c and R d are independently hydrogen or -C1-C4 alkyl, R b It is an alkyl group.
[0103] The term "cycloalkylene" refers to a divalent cycloalkyl group as defined herein.
[0104] The term "C3-C6 cycloalkoxy" refers to a three- to six-membered cycloalkyl group attached to an oxy group. Examples include cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, and cyclohexyloxy.
[0105] In some cases, the number of atoms in a ring substituent containing one or more heteroatoms (i.e., a heteroaryl or heterocycloalkyl) is indicated by the prefix "x- to y-membered", where x is the minimum number of atoms forming the substituted ring molecule and y is the maximum number of atoms forming the substituted ring molecule. Thus, for example, "4- to 6-membered heterocycloalkyl" refers to a heterocycloalkyl containing 4 to 6 atoms (including 1 to 3 heteroatoms) in the heterocycloalkyl ring molecule. Similarly, the term "5- to 6-membered heteroaryl" refers to a heteroaryl containing 5 to 6 heteroatoms and "5- to 10-membered heteroaryl" refers to a heteroaryl containing 5 to 10 atoms in a 30 heteroaryl ring molecule, each of which includes one or more heteroatoms. In addition, the terms "5-membered heteroaryl" and "6-membered heteroaryl" may refer to a five-membered heteroaromatic ring system and a six-membered heteroaromatic ring system, respectively. The heteroatoms present in these ring systems are selected from N, O and S.
[0106] The term "hydroxy" refers to -OH. When used in combination with another term, the prefix "hydroxy" indicates that the substituent to which the prefix is attached is replaced by one or more hydroxy substituents. Compounds having a carbon with one or more hydroxy substituents include, for example, alcohols, enols, and phenols. The terms cyano and nitrile refer to the -CN group. The term "oxo" refers to an oxygen attached to a carbon by a double bond (i.e., when R 4 When it is oxygen, R 4 Together with the carbon to which it is attached is a C=O molecule).
[0107] The term "hydroxyalkyl" refers to an alkyl group as defined herein substituted with 1, 2 or 3 hydroxy groups.
[0108] The term "halogen" or "halogen" refers to fluorine (depicted as -F), chlorine (depicted as -Cl), bromine (depicted as Br), or iodine (depicted as -I).
[0109] The term "haloalkyl" refers to an alkyl group as defined herein substituted with 1, 2, 3, 4, 5, 6 halo groups. In some embodiments, haloalkyl includes chloroalkyl.
[0110] The term "heterocycloalkyl" refers to a substituent obtained by removing hydrogen from a saturated or partially saturated ring structure, the saturated or partially saturated ring structure comprising a total of a specified number of atoms, such as 4-6 ring atoms or 4-12 atoms, wherein at least one ring atom is a heteroatom (i.e., oxygen, nitrogen or sulfur), and the remaining ring atoms are independently selected from carbon, oxygen, nitrogen and sulfur. Sulfur may be oxidized [i.e., S(O) or S(O)2] or not oxidized. In a group having a heterocycloalkyl substituent, the heterocycloalkyl substituent ring atom combined with the group may be a nitrogen heteroatom or a ring carbon atom. Similarly, if the heterocycloalkyl substituent is replaced by a group or a substituent, the group or substituent may be combined with a nitrogen heteroatom or may be combined with a ring carbon atom. It should be understood that the heterocyclic group may be monocyclic, bicyclic, polycyclic, bridged, or spirocyclic. In addition to any groups specifically listed in any embodiment or claim, in some structures, the heterocycloalkyl group is optionally substituted with 1-3 substituents independently selected from halogen, -C1-C 12 Alkyl (unsubstituted or substituted, in one embodiment with 1, 2, or 3 halogenated groups), aryl, -OH, -OC1-C 12 Alkyl, -S(O) n C1-C4 alkyl (where n is 0, 1, 2), -C1-C4 alkyl NH2, -NHC1-C4 alkyl, -C(=O)H, C(=O)OR a 、-OC(=O)R b 、OC(=O)NR a R c , OC(=O)heteroaryl and OC(=O)(heterocyclyl), wherein R a , R c and R d are independently hydrogen or -C1-C4 alkyl, and R b It is an alkyl group.
[0111] The term "aryl" refers to a carbocyclic monocyclic or bicyclic ring system, wherein the monocyclic ring is aromatic and the bicyclic ring includes at least one aromatic ring. 10"Aryl" refers to a carbon ring system having 6 to 10 atoms, including phenyl, tetrahydronaphthyl and naphthyl. In addition to any groups specifically listed in any embodiment or claim, in some structures, aryl is optionally substituted with 1-3 substituents independently selected from halogen, -C1-C 12 Alkyl (unsubstituted or substituted, in one embodiment with 1, 2, or 3 halogenated groups), aryl, -OH, -OC1-C 12 Alkyl, -S(O) n C1-C4 alkyl (where n is 0, 1, 2), -C1-C4 alkyl NH2, -NHC1-C4 alkyl, -C(=O)H, C(=O)OR a 、-OC(=O)R b 、OC(=O)NR a R c , OC(=O)heteroaryl and OC(=O)(heterocyclyl), wherein R a , R c and R d are independently hydrogen or -C1-C4 alkyl, and R b It is an alkyl group.
[0112] The term "arylene" as used herein refers to a divalent aromatic radical as defined herein.
[0113] The term "heteroalkyl" refers to an alkyl group as defined herein, wherein one or more -CH2- is substituted by a group independently selected from -O-, -S-, -S(O)-, -S(O)2 and -NR-, wherein R is hydrogen or alkyl, as defined herein, and / or wherein one or more -CH3 groups are substituted by a group independently selected from -OH, -SH and -NH2, wherein each R is independently hydrogen or alkyl. Heteroalkyl includes 2-thioethyl, 2-amino-P-1-yl, 2-hydroxy-ethyl-1-yl, N-methyl-amino-ethyl, etc. Hydroxyalkyl is a subset of heteroalkyl.
[0114] The term "heteroalkylene" refers to a divalent heteroalkyl group as defined herein.
[0115] The term "heteroaryl" refers to an aromatic ring structure containing a specified number of ring atoms, wherein at least one ring atom is a heteroatom (i.e., oxygen, nitrogen, and / or sulfur) and the remaining ring atoms are carbon. Examples of heteroaryl substituents include 6-membered heteroaryl rings, such as pyridyl, pyrazolyl, pyrimidinyl, and pyridazinyl; and 5-methylheteroaryl rings, such as triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazinyl, 1,3,4-oxadiazolyl, and isothiazolyl. Heteroaryl can also be a bicyclic heteroaryl, such as indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, oxazolopyridinyl, imidazopyridinyl, and imidazopyrimidinyl, etc. In a group having a heteroaromatic ring, the ring atom of the heteroaromatic ring to which the group is bound may be a nitrogen atom or a ring carbon atom. Similarly, if the heteroaromatic ring is in turn substituted by a group or a substituent, the group or substituent may be bound to a nitrogen atom or may be bound to a ring carbon atom. The term "heteroaryl" also includes pyridyl N-oxides and groups containing pyridine N-oxide rings. In addition, the heteroaryl group may contain an oxo group, such as the oxo group present in a pyridone group. Further examples include furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridinediyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridin-2(1H)-acyl, pyridazin-2(1H)-acyl, pyrimidin-2(1H)-acyl, imidazo[1,2-a]pyridinyl and pyrazolo[1,5-propyridinyl]. The heteroaryl group may be further substituted as defined herein.
[0116] Examples of monocyclic heteroaryl and heterocycloalkyl groups include furanyl, dihydrofuranyl, tetrahydrofuranyl, thiophenyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, isopyrazolidinyl, pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolidinyl, imidazolinyl, pyrazolinyl, pyrazolidinyl, pyrazalidinyl, thiozolyl, tetrazolyl, dithio, oxathio, oxazolidinyl, isoxazolyl, thiazolyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, thiadiazolyl, oxathiazolyl, oxadiazolyl {including oxadiazolyl, 1,2,4-oxadiazolidinyl, 1,2,5-oxadiazinyl, 1,3,4-oxatriazolyl), pyranyl 1,2-pyranyl or 1,4-pyranoyl), dihydropyranyl, pyridyl, piperidyl, diazinyl (including pyridazinyl, pyrimidinyl, piperazinyl, triazinyl (including s-triazinyl, as-triazinyl and v-triazinyl), oxazinyl (including 2H-1,2-oxazinyl, 6H-1,3-oxazinyl, 2H-1,4-oxazinylbutyl, isoxazolidinyl (including O-isoxazolyl zincyl or p-isoxazolinyl), oxazolidinyl, isoxazolidine, thiazinyl (including 1,2,5-thiazinyl or 1,2,6-thiazinyl), oxadiazinyl (including 2H1,2,4-oxadiazinyl or 2H1,2,5-oxadiazinyl) and morpholinyl.
[0117] When so specified, the term "heteroaryl" may also include ring systems having two rings, wherein the rings may be fused and one of the rings is aromatic while the other ring is not completely part of a diconjugated aromatic system (i.e., the heteroaromatic ring may be fused to a cycloalkyl or heterocycloalkyl ring). Non-limiting examples of such ring systems include 5,6,7,8-tetrahydroisoquinolyl, 5,6,7,8-tetrahydroquinolyl, 6,7-dihydro-5H-cyclopentyl[b]pyridinyl, 6,7-dihydro-5-cyclopentyl[c]pyridinyl, 1,4,5,6-tetrahydrocyclopentyl[c]pyrazolyl, 2,4,5,6-tetrahydrocyclopentyl[c]pyrazolyl, 5,6-dihydro-4H-pyrazol ... pyrrolo[1,2-b]pyrazolyl, 6,7-dihydro-5H-pyrrolo[1,2-b[1,2,4]triazolyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridinyl, 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine, 4,5,6,7-tetrahydro-1H-indazolyl and 4,5,6,7-tetrahydroxy-2H-indolizinyl.
[0118] It should be understood that if a carbocyclic or heterocyclic molecule can be bonded or otherwise attached to a specified group through different ring atoms, without indicating a specific point of attachment, all possible points are referred to, whether through a carbon atom or, for example, a trivalent nitrogen atom. For example, the term "pyridyl" means 2-, 3-, 4-pyridyl, the term "thienyl" means 3- or 2-thienyl, and so on.
[0119] The term "heteroarylene" as used herein refers to a divalent heteroaryl group as defined herein.
[0120] The term "amino protecting group" refers to a group that prevents the amino from reacting when the other parts of the molecule react and can be easily removed. Non-limiting examples include 9-fluorenylmethoxycarbonyl, tert-butyloxycarbonyl, acetyl, benzyl, allyl, p-methoxybenzyl, etc. These groups can be optionally substituted by one to three substituents selected from halogen, alkoxy and nitro. The amino protecting group is preferably 9-fluorenylmethoxycarbonyl.
[0121] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
[0122] The term "unsaturated" in the context of the terms cycloalkyl, cycloalkylene and heterocyclyl refers to a partially unsaturated but non-aromatic ring.
[0123] The term "fused" refers to a bicyclic, tricyclic or polycyclic structure composed of at least two carbocyclic or heterocyclic structures that share at least one chemical bond.
[0124] If a substituent is described as having more than one variable "independently," each instance of the substituent is independently selected from the list of available variables. Thus, each substituent may be the same as or different from the other substituents.
[0125] If a substituent is described as being "independently selected" from a group, each instance of the substituent is selected independently of the other instances. Thus, each substituent may be the same as or different from the other substituents.
[0126] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur. For example, "aryl optionally mono- or di-substituted with alkyl" means that alkyl may but need not be present, and that the description includes instances where aryl is mono- or di-substituted with alkyl and instances where aryl is not substituted with alkyl.
[0127] "Substituted" refers to one or more hydrogen atoms in a group, preferably up to 5, more preferably 1-3 hydrogen atoms, independently replaced by a corresponding number of substituents. Needless to say, substituents are present only in their possible chemical positions. Those skilled in the art can determine by experiment or theory whether substitution is possible or not without undue effort. For example, the combination of an amino or hydroxyl group with free hydrogen and a carbon atom with an unsaturated bond (such as an olefinic group) may be unstable.
[0128] As used in this application, the term "compound of formula (I)" (or other general formula numbering) is defined to include all forms of the compound of formula 1, including hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs and metabolites thereof. For example, the compounds disclosed in the present application or pharmaceutically acceptable salts thereof may exist in undissolved and solvated forms. When the solvent or water is tightly bound, the complex will have a clear stoichiometry, regardless of humidity. However, when the solvent or water is weakly bound, such as in channel solvates and hygroscopic compounds, the water / solvent content will depend on humidity and drying conditions. In this case, non-stoichiometry will be the norm. Compounds with the same molecular formula but different atomic bonding properties or orders or different arrangements of atoms in space are referred to as "isomers". Isomers with different arrangements of atoms in space are referred to as "stereoisomers".
[0129] Stereoisomers that are not mirror images of one another are termed "diastereomers," while those that are non-superimposable mirror images of one another are termed "enantiomers." For example, when a compound has an asymmetric center, it binds to four different groups, and a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center, and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way the molecule rotates the plane of polarized light, and designated as right- or left-handed (i.e., (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."
[0130] The compounds provided herein may have one or more asymmetric centers; such compounds may therefore be produced as individual (R)- or (S)-stereoisomers or mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in the specification and claims is intended to include its individual enantiomers and mixtures, racemates or other forms. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see "Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 1992).
[0131] Hydrogen (H) or carbon (C) substitution of the compounds of Formulas I to VIII includes substitution with any isotope of the corresponding atom. Thus, hydrogen (H) substitution includes 1H, 2H (deuterium) or 3H (tritium) isotope substitution, which may be desirable, for example, for specific therapeutic or diagnostic treatments, or metabolic research applications, or metabolic or chemical stability enhancement. Optionally, the compounds of the present application may incorporate radioactive isotopes known in the art, such as 3H. 15 O. 12 C or 13 N isotope to provide the corresponding radiolabeled compound of formula I.
[0132] "Pharmaceutically acceptable carrier" means a carrier that can be used to prepare a pharmaceutical composition that is generally safe, non-toxic, neither biologically significant nor otherwise undesirable, including carriers that can be used for veterinary and human pharmaceutical purposes. "Pharmaceutically acceptable carrier" as used in the specification and claims includes one or more such carriers.
[0133] A "pharmaceutically acceptable salt" of a compound refers to a salt that is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. Such salts include: (1) Acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentene propionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2- Hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, mucic acid, etc.; or (2) Salts formed when the acidic protons present in the parent compound are replaced by metal ions, such as alkali metal ions, alkaline earth ions or aluminum ions; or coordinated with organic bases such as ethanolamine, diethanolamine, triethanolamine, butanetriolamine, N-methylglucamine, etc.
[0134] "Treatment" for illness includes: (1) To prevent a disease, even if clinical symptoms of the disease will not develop in a mammal that may be exposed to or susceptible to the disease but does not yet experience or show symptoms of the disease, (2) inhibit the disease, i.e., prevent or reduce the development of the disease or its clinical symptoms, or (3) Relieve the disease, that is, cause the disease or its clinical symptoms to disappear.
[0135] The term "pharmaceutical composition" refers to a mixture of one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs with other chemical components, and other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compound to an organism, which is beneficial to the absorption of the active ingredient, thereby showing biological activity.
[0136] The term "solvate" refers to a pharmaceutically acceptable solvate formed by the ligand-drug conjugate of the present application and one or more solvent molecules. Non-limiting examples of solvent molecules include water, ethanol, acetonitrile, isopropanol, DMSO, and ethyl acetate.
[0137] The term "carrier" used in the composition of the present application refers to a system that can change the way a drug enters the human body and is distributed, control the drug release rate, and deliver the drug to the target organ. The drug carrier release and targeting system can reduce drug degradation and loss, reduce side effects, and improve bioavailability.
[0138] The term "excipient" refers to auxiliary materials in pharmaceutical preparations other than the main drug, which can also be called adjuvants, such as binders, fillers, disintegrants, lubricants in tablets; the matrix part in semi-solid preparations ointments and creams; preservatives, antioxidants, flavorings, fragrances, cosolvents, emulsifiers, solubilizers, osmotic pressure regulators, colorants in liquid preparations, etc.
[0139] The term "diluent", also known as filler, is mainly used to increase the weight and volume of the tablet. The addition of diluent ensures a certain volume, reduces the dosage deviation of the main ingredients, and improves the compression characteristics of the drug. When the tablet contains oily ingredients, absorbents are added to absorb the oily substances, thereby maintaining a "dry" state to facilitate tablet formation. For example, diluents include starch, lactose, inorganic salts of calcium, microcrystalline cellulose, etc.
[0140] The pharmaceutical composition can be in the form of a sterile injectable aqueous solution. Acceptable carriers or solvents that can be used are water, Ringer's solution or isotonic sodium chloride solution. The sterile injectable preparation can be a sterile injectable oil-in-water microemulsion, in which the active ingredient is dissolved in the oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol and processed to form a microemulsion. The injectable solution or microemulsion can be introduced into the patient's blood by local bolus injection. Alternatively, the solution and microemulsion are preferably administered in a manner that maintains a constant circulating concentration of the compound of the present disclosure. In order to maintain this constant concentration, a continuous intravenous delivery device can be used. Deltec CADD-PLUS TM The 5400 IV Pump is an example of such a device.
[0141] The pharmaceutical composition can be in the form of a sterile injectable aqueous or oily suspension for intramuscular and subcutaneous administration. According to known techniques, such suspensions can be prepared with suitable dispersants or wetting agents and suspending agents as described above. Sterile injectable preparations can also be sterile injectable solutions or suspensions prepared in nontoxic parenteral acceptable diluents or solvents, such as solutions prepared in 1,3-butanediol. In addition, sterile fixed oils can be easily used as solvents or suspension media. For this purpose, any mixed fixed oils can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids, such as oleic acid, can also be used to prepare injections.
[0142] The term "drug loading" refers to the average number of cytotoxic drugs loaded on each ligand in the compound of formula (I), and can also be expressed as the ratio of the number of drugs to the number of antibodies. The drug loading of each ligand can be in the range of 0 to 12, preferably 1 to 10 cytotoxic drugs. In the embodiments of the present application, the drug loading is expressed as n, and exemplary values can be an average value of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. The average number of drugs per ADC molecule after the coupling reaction can be determined by conventional methods such as UV / visible spectroscopy, mass spectrometry, ELISA testing and HPLC characterization.
[0143] "Therapeutically effective amount" refers to the amount of a compound that is sufficient to treat a disease when administered to a mammal to treat the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc. of the mammal to be treated.
[0144] The term "mammal" refers to all mammals, including humans, livestock, and companion animals.
[0145] The compounds described herein are generally named according to the IUPAC or CAS naming system. Abbreviations well known to those of ordinary skill in the art can be used (e.g., "Ph" means phenyl, "Me" means methyl, "Et" means ethyl, "h" means hours or hours, and "rt" or "rt" means room temperature). Synthesis method of the present application
[0146] Solution 1
[0147] A method for preparing a compound of formula (D4) according to formula (V) of the present application or a pharmaceutically acceptable salt or solvate thereof comprises the following steps: Step 1: reacting a compound of formula (D1) with D2 under acidic conditions to obtain a compound of formula (D3); Step 2: reducing the compound of formula (D3) to obtain a compound of formula (D4); Step 1: reacting the compound of formula (D1) with D2 under acidic conditions to obtain a compound of formula (D3); Step 2: Deprotecting the compound of formula (D3) to obtain a compound of formula (D4); Where: X, R 2 , R 3 , R 4 , n is as defined in formula (V) and any of its embodiments; PG is an amino protecting group, and is preferably benzyloxycarbonyl (Cbz). The reagents providing alkaline conditions include organic bases and inorganic bases. Organic bases include, but are not limited to, triethylamine, diethylamine, N-methylmorpholine, pyridine, piperidine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide, and potassium tert-butoxide. Inorganic bases include, but are not limited to, sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, and lithium hydroxide.
[0148] Option 2:
[0149] A method for preparing a compound of formula (D3 or D5 or D6) or a pharmaceutically acceptable salt or solvate thereof according to formula (IV) of the present application comprises the following steps: Step 1: reacting a compound of formula (D1) with a compound of formula (D2) in the presence of a condensing agent to obtain a compound of formula (D3); Step 1: reacting the compound of formula (D1) with 1-((chloromethoxy)methyl)-4-nitrobenzene to obtain a compound of formula (D2); Step 2: reducing the compound of formula (D2) to obtain a compound of formula (D3); Step 3: reacting a compound of formula (D3) with a compound of formula (D4) in the presence of a condensing agent to obtain a compound of formula (D5); Where: X, R 2 , R 3 , R 4 , n, w, L 2 , L 3 , L 4 As defined in formula (IV) and any of its examples; PG is an amino protecting group, and is preferably benzyloxycarbonyl (Cbz). The reagents providing alkaline conditions include organic bases and inorganic bases. Organic bases include, but are not limited to, triethylamine, diethylamine, N-methylmorpholine, pyridine, piperidine, N,N-diisopropylethylamine, n-butyllithium, lithium diisopropylamide, potassium acetate, sodium tert-butoxide, and potassium tert-butoxide. Inorganic bases include, but are not limited to, sodium hydride, potassium phosphate, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, and lithium hydroxide. The condensing agent is selected from 4-(4.6-dimethoxy-1.3.5-triazine-2-yl)-4-methyl-dimorpholine chloride, 1-hydroxybenzotriazole, 1-(3-dimethylaminopropyl)-3-ethylcarbodiamide hydrochloride, N,N'-dicyclohexylcarbodiamide, N,N'-dipropylcarbodiamide, O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1-hydroxybenzotriazole, 1-hydroxy-7-azobenzotriazole, O-benzotriazole-N,N,N' , N'-tetramethyluronium hexafluorophosphate, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, benzotriazole-1-acyloxytris(dimethylamino)-hexafluorophosphate and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate, preferably 4-(4.6-dimethoxy-1.3.5-triazine-2-yl)-4-methyl-dimorpholine chloride, 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiamide hydrochloride.
[0150] Solution 3
[0151] A method for preparing a compound of formula (III) and any embodiment thereof (D9 or D11) or a pharmaceutically acceptable salt or solvate thereof according to the present application comprises the following steps: After reduction, T is coupled with a compound of formula D8 or D10 to obtain a ligand-drug conjugate of formula D9 or D11; the reducing agent is preferably TCEP; in: T is the ligand; X, R 1a , R 2 , R 3 , R 4 , n, w, L 2 , L 3 , L 4 , q is as defined in formula (III) or any embodiment thereof.
[0152] The present application will be further described with reference to the following examples, but these examples should not be construed as limiting the scope of the present application. The experimental methods in the present application examples that do not specify specific conditions are carried out according to conventional conditions or conditions recommended by material or product manufacturers. Reagents that do not specify specific sources are conventional reagents purchased from the market. Example
[0153] Example 1
[0154] To a solution of 1-6 (70 mg, 0.291 mmol) in toluene (4.00 mL) was added MRB-WX-014 ( 76.71 mg, 0.29 mmol) and 4-methylbenzenesulfonic acid (50.18 mg, 0.29 mmol). The resulting mixture was then stirred at 110°C for 12 hours. LCMS showed that the reaction was complete. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by prep-HPLC (Phenomenex C18 100*40mm*3um; mobile phase: [A%: water (TFA)-B%: ACN]; B%: 20%-50%, 8 minutes) to give a yellow solid 1-7 (15.00 mg, 0.03 mmol, yield 11.47%). LC-MS: 450.1[M+H] + .
[0155] Pd / C (10%, 2.28 mg, 0.002 mmol) was added to a solution of 1-7 (10.00 mg, 0.02 mmol) in 2,2,2-trifluoroethane-1-ol (1.00 mL) under N2. The resulting suspension was degassed under vacuum and purged with H2 several times. The mixture was then stirred at 25°C and H2 (15 Psi) for 20 minutes. LCMS showed that the reaction was complete. The reaction mixture was filtered and the filtrate was purified by prep-HPLC (chromatographic column: Phenomenex Luna C18 75*30mm*3um; mobile phase: [A%: water (TFA)-B%: ACN]; B%: 5%-35%, 8 minutes) to give the compound of Example 1 as a yellow solid (3.96 mg, 0.009 mmol, yield 21.21%).
[0156] LC-MS:420.2[M+H] + .
[0157] 1H NMR (400MHz, METHANOL-d4) δ7.66(d,J=9.0Hz,1H),7.56(s,1H),7.38(br dd,J=8.5,3.8Hz,2H),6.79(br d,J=9.6Hz,1H),5.66-5.55(m,1H),5.40(d,J=16.3Hz,1H),5.06(br s,2H),1.97(br dd,J=7.3,4.7Hz,2H),1.02(t,J=7.4Hz,3H).
[0158] Example 2
[0159] The compound of Example 2 was synthesized according to the procedure described in Example 1.
[0160] LC-MS:438.1[M+H] + .
[0161] 1 H NMR (400MHz, DMSO-d6) δ7.49(d,J=12.4Hz,1H),7.36(d,J=10.0Hz,1H),7.11(s,1H),6.79(d,J=10.0Hz,1H ), 6.46 (s, 1H), 5.56 (s, 2H), 5.39 (s, 2H), 5.02 (s, 2H), 1.84 (td, J = 14.0, 6.9Hz, 2H), 0.86 (t, J = 7.3Hz, 3H).
[0162] Example 4
[0163] The compound of Example 4 was synthesized according to the procedure described in Example 1.
[0164] LC-MS: 434.0[M+H] + .
[0165] 1 H NMR (400MHz, DMSO-d6): δ7.51(s,1H),7.29(d,J=10.0Hz,1H),7.10(s,1H),6.73(d,J=10.0Hz,1H),6.45(s, 1H),5.46-5.36(m,2H),5.19-5.11(m,2H),5.00(s,2H),2.35(s,3H),1.85(td,J=13.4,6.9Hz,2H),0.87(br t,J=7.3Hz,3H).
[0166] Example 5
[0167] The compound of Example 5 was synthesized according to the procedure described in Example 1.
[0168] LC-MS:450.2[M+H] + .
[0169] 1 H NMR (400MHz, DMSO-d6): δ7.31(d,J=10.0Hz,1H),7.20(s,1H),7.13(s,1H),6.73(d,J=10. 0Hz, 1H), 5.40 (s, 2H), 5.00 (s, 2H), 3.97 (s, 3H), 1.91-1.78 (m, 2H), 0.86 (t, J = 7.3Hz, 3H).
[0170] Example 9
[0171] To a solution of 9-1 (20 g, 86.196 mmol) in dioxane (200 mL) was added ethyl 3-thiopropionate (13.88 g, 103.435 mmol), DIEA (30 mL, 22.28 g, 172.392 mmol), Xantphos (9.98 g, 17.239 mmol) and Pd2(dba)3 (7.89 g, 8.620 mmol) at 25 ° C. The mixture was degassed and purged with N2 for 3 times, and then stirred at 90 ° C, N2 for 4 hours. LCMS, TLC (petroleum ether / ethyl acetate = 3 / 1) showed that 9-1 was completely consumed and the MS of the expected compound was detected. The reaction mixture was cooled to room temperature, quenched with water (100 mL), and extracted with ethyl acetate (100 mL×2). The combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by SGC (petroleum ether / ethyl acetate=10 / 1 to 1 / 1) to obtain yellow solid 9-2 (20 g, 70.099 mmol, yield 81.33%). LC-MS: 286.2 [M+H] + .
[0172] Pd / C (10%, 1.96 g, 18.430 mmol) was added to a solution of 9-2 (25 g, 92.152 mmol) in MeOH (300 mL) under N2. The mixture was degassed and purged with H2 three times, and then stirred at 25°C, H2 (15 psi) for 12 hours. LCMS showed that 9-2 was completely consumed. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to obtain a crude product 9-3 (25 g, 88.061 mmol, yield 95.56%) as a yellow solid, which was used directly in the next step without purification. LC-MS: 256.2 [M+H] + .
[0173] A solution of 9-3 (25 g, 97.913 mmol) in HCl (6 M, 489.563 mL) was stirred at 60 ° C for 12 hours. LCMS showed that SM was completely consumed. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was slurried with EtOAc / MTBE=1 / 1 (200 mL), filtered and the solid was collected to give a yellow solid 9-4 (22 g, 96.797 mmol, yield 98.86%). LC-MS: 228.2 [M+H] + .
[0174] To a solution of 9-4 (11 g, 48.398 mmol) in TFA (110 mL) was added TFAA (101.65 g, 483.985 mmol) at 25 ° C. The mixture was then stirred at 25 ° C for 12 hours. LCMS and TLC (petroleum ether / ethyl acetate = 3 / 1) showed that 9-4 was completely consumed and the MS of the expected product was detected. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 1 / 1) to give a yellow solid 9-5 (12 g, 39.309 mmol, yield 81.22%). LC-MS: 304.1 [M-1] - .
[0175] K2CO3 (5.43 g, 39.309 mmol) was added to a solution of 9-5 (6 g, 19.655 mmol) in MeOH (60 mL) at 25°C. The mixture was then stirred at 25°C for 12 hours. TLC (petroleum ether / ethyl acetate = 3 / 1) showed that 9-5 was completely consumed. The pH of the mixture was adjusted to ~4 by slowly adding HCl solution (2M). The residue was diluted with water (50 mL) and extracted with DCM (100 mL×2). The combined organic layers were dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a crude product 9-6 (5 g, 19.115 mmol, 97.25% yield, yellow oil), which was used directly in the next step without purification.
[0176] To a toluene (10 mL) solution of 9-6 (400 mg, 1.529 mmol) was added (4S)-4-ethyl-4-hydroxy-3,4,6,7,8,10-hexahydro-1H-pyrano[3,4-f]indoline-3,6,10-trione (402.56 mg, 1.529 mmol) and 4-methylbenzenesulfonic acid (263.33 mg, 1.529 mmol) at 25 ° C. The mixture was then stirred at 105 ° C for 12 hours. LCMS showed that SM was completely consumed and MS of the expected product was detected. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was slurried with ethyl acetate (10.0 mL), filtered and the solid was collected to give a yellow solid 9-7 (900 mg, 1.443 mmol, yield 94.39%). LC-MS: 437.2 [M + H] + .
[0177] To a solution of 9-7 (1 g, 2.291 mmol) in dioxane (5 mL) was added DDQ (0.78 g, 3.437 mmol) at 25 °C under N2. The reaction mixture was then stirred at 105 °C for 2 hours. LCMS and HPLC showed that most of 9-7 was consumed, and the MS of the expected product was detected. The reaction mixture was concentrated under reduced pressure. The residue was slurried with ethyl acetate (5.0 mL), filtered and the solid was collected. The residue was purified twice by prep-HPLC (FA conditions) to give a brown solid 9-8 (50 mg, 0.115 mmol, yield 5.02%). LC-MS: 435.1 [M+H] + .
[0178] A solution of 9-8 (25 mg, 0.058 mmol) in HBr (2 mL) was stirred at 100° C. for 1 hour. LCMS (MCP230760-015-P1A) showed that most of 9-8 was consumed, and the MS of the expected product was detected. The mixed solution was purified by prep-HPLC (FA conditions) without treatment to obtain the compound of Example 9 (6.64 mg, 0.015 mmol, 26.79% yield) as a red solid.
[0179] LC-MS:421.2[M+H] + .
[0180] 1H NMR (400MHz, DMSO-d6) δ8.49-8.35(m,1H),7.60(br d,J=9.0Hz,1H),7.32(brd,J=9.0Hz,1H),7.26(br d,J=10.0Hz,1H),7.14-7.08(m,1H),6.70(br d,J=10.0Hz,1H),6.54-6.38(m,1H),5.46-5.33(m,2H),5.06-4.93(m,2H),1.85(tt,J=13.8,7.1Hz,2H),0.87(br t,J=7.3Hz,3H).
[0181] The following compounds were synthesized according to the procedure described in Example 1.
[0182] Example 12
[0183] The compound of Example 12 was synthesized according to the procedure described in Example 1. LC-MS:454.1[M+H] + . 1 H NMR (400MHz, DMSO-d6): δ7.42-7.37(m,2H),7.31-7.26(m,1H),7.18(br d,J=5.0Hz,1H),6.87-6.79(m,1H),6.74-6.58(m,1H),6.54-6.41(m,1H),5.52(s,1H),5.43-5.28(m,2H),5.03(s,1H),2.00(br d,J=7.5Hz,2H),0.86(br d,J=2.6Hz,3H).
[0184] Embodiment 13
[0185] Compound 13-2 (167 mg, 0.536 mmol), DMAP (131 mg, 1.07 mmol) and EDCI (103 mg, 0.536 mmol) were added to a solution of the compound of Example 1 (150 mg, 0.358 mmol) in DCM (2.00 mL) at 25°C. The resulting mixture was then stirred at 25°C for 12 hours. LCMS showed that the compound of Example 1 was completely consumed and the MS of the expected product was detected. The reaction mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (chromatographic column: Phenomenex Luna C18 80*30mm*3um; mobile phase: [A: H2O (0.1% TFA); B: ACN]; B%: 55.00%-90.00%, 8.00 minutes) to give a brown solid 13-1 (80 mg, 0.112 mmol, yield 31.3%). LC-MS: 716.2[M+H] + .
[0186] To a solution of 13-1 (40.0 mg, 0.056 mmol) in DCM (4.00 mL) was added a solution of hydrogen chloride (g) in dioxane (0.140 mL, 0.559 mmol) at 25°C, and the mixture was stirred at 25°C for 1 hour. LCMS showed that 13-1 was completely consumed and the MS of the expected product was detected. The reaction mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (chromatographic column: Phenomenex Luna C18 75*30mm*3um; mobile phase: [A: H2O (0.1% TFA); B: ACN]; B%: 15.00%-45.00%, 8.00 minutes) to give a brown solid 13 (17.0 mg, 0.036 mmol, yield 63.9%).
[0187] LC-MS:478.2[M+H] + .
[0188] 1 H NMR (400MHz, DMSO-d6): δ7.57(d,J=9.0Hz,1H),7.27(dd,J=9.5,7.0Hz,2H),6.83(s,1H),6.72(d,J=10.0Hz,1H),5.61(s,1H),5.48(br d,J=2.6Hz,3H),5.02(s,2H),4.36-4.12(m,1H),2.15-2.05(m,2H),0.95-0.86(m,3H).
[0189] Embodiment 14
[0190] Triphosgene (25.5 mg, 0.086 mmol) was added to a mixture of Example 1 compound (30.0 mg, 0.072 mmol) and Py (0.069 mL, 0.858 mmol) in DCM (5.00 mL) at -78 °C. The mixture was stirred at -78 °C, N2 for 3 hours, and then a THF (5.00 mL) solution of 14-1 (15.1 mg, 0.086 mmol) was added at -78 °C. The reaction mixture was heated to 25 °C and stirred for 12 hours. LCMS showed that SM was completely consumed, and MS of the expected product was detected. The reaction mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (chromatographic column: 3_Phenomenex Luna C18 75*30mm*3um; mobile phase: [A: H2O (0.2% FA); B: ACN]; B%: 10.00%-40.00%, 8.00 minutes) to give a red solid 14 (13.29 mg, 0.026 mmol, yield 36.37%).
[0191] LC-MS: 508.25[M+H] + .
[0192] 1 H NMR (400MHz, MeOD-d4): δ7.80-7.74(m,1H),7.72-7.66(m,1H),7.59(s,1H),7.35(d,J=10.0Hz,1H),6.90(d,J=10.0Hz,1H),5.65- 5.56(m,1H),5.41(d,J=16.4Hz,1H),5.13(s,2H),4.29-4.23(m,2H),3.87-3.75(m,2H),2.09-1.88(m,2H),1.03(t,J=7.4Hz,3H).
[0193] Embodiment 15
[0194] To a mixture of the compound of Example 1 (50.00 mg, 0.12 mmol) in DCM (10.00 mL) were added N-{[(2-methylpropan-2-yl)oxy]carbonyl}-L-alanine (45.11 mg, 0.24 mmol) and EEDQ (58.96 mg, 0.24 mmol). The mixture was then stirred at 25°C for 72 hours. LCMS showed that the reaction was complete. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (chromatographic column: Phenomenex luna C18 100*40mm*5um; mobile phase: [A%: water (TFA)-B%: ACN]; B%: 20%-45%, 8 minutes) to give a yellow solid 15-1 (10.00 mg, 0.02 mmol, yield 14.20%). LC-MS: 591.1 [M+H] + .
[0195] TFA (0.70 mL, 9.14 mmol) was added to a solution of 15-1 (10.00 mg, 0.02 mmol) in DCM (2.00 mL), and the resulting mixture was stirred at 25 ° C for 1 hour. LCMS showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain a yellow oily crude product 15-2 (8.00 mg, 0.02 mmol, yield 96.33%), which was used directly in the next step without purification. LC-MS: 491.1 [M+H] + .
[0196] To a solution of 15-2 (5.00 mg, 0.01 mmol) in DMF (2.00 mL) was added N-{[(2-methylpropan-2-yl)oxy]carbonyl}-L-valine (2.21 mg, 0.01 mol), NMM (0.004 mL, 0.04 mmol) and DMTMMT (3.20 mg, 0.01 mmol). The resulting mixture was then stirred at 25 °C for 12 hours. LCMS showed that the reaction was complete. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (chromatographic column: Phenomenex Kinetex EVO C18 150*30mm5um; mobile phase: [A%: water (TFA)-B%: ACN]; B%: 25%-55%, 20 minutes) to give a yellow solid 15-3 (3.00 mg, 0.004 mmol, yield 42.67%). LC-MS: 690.3[M+H] + .
[0197] A solution of 15-3 (3.00 mg, 0.004 mmol) in TFA (0.30 mL) and DCM (0.90 mL) was stirred at 25 °C for 10 minutes. LCMS showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to give a yellow oil 15-4 (2.00 mg, 0.003 mmol, crude product). LC-MS: 590.3 [M+H] + .
[0198] MRX-110 (2.01 mg, 0.003 mmol), NMM (0.001 mL, 0.014 mmol) and DMTMMT (1.07 mg, 0.003 mmmol) were added to a solution of 15-4 (2.00 mg, 0.003 mmol) in DMF (1.00). The resulting mixture was then stirred at 25 °C for 12 hours. LCMS showed that the reaction was complete. The residue was purified by prep-HPLC (chromatographic column: Phenomenex Gemini NX 150*30 mm*5 um; mobile phase: [A%: water (TFA)-B%: ACN]; B%: 15%-40%, 20 minutes) to give a yellow solid 15 (1.22 mg, 0.001 mmol, yield 30.89%).
[0199] LC-MS: 583.5[1 / 2M+H] + .
[0200] 1 H NMR (400MHz, METHANOL-d4): δ8.32(br d,J=6.2Hz,1H),8.08-7.99(m,1H),7.73(d,J=9.0Hz,1H),7.57(s,1H),7.55(s,1H),7.33(d,J=10.0Hz,1H),6.88(s ,1H),6.81(s,2H),5.60(s,1H),5.41(s,1H),3.76(t,J=6.8Hz,4H),3.65-3.59(m,30H),3.52-3.45(m,4H),2.57(br t,J=5.6Hz,2H),2.45(t,J=6.9Hz,2H),2.22-2.08(m,1H),2.00-1.87(m,2H),1.55(br d,J=7.1Hz,3H),1.04-0.98(m,9H).
[0201] The following compounds were synthesized according to the procedure described in Example 15.
[0202] Embodiment 21
[0203] To a mixture of the compound of Example 1 (0.20 g, 0.48 mmol) in DCM (10.00 mL) was added N-{[(2-methylpropan-2-yl)oxy]carbonyl}glycine (167.06 mg, 0.95 mmol) and EEDQ (235.82 mg, 0.95 mmol). The mixture was then stirred at 25° C. for 12 hours. LCMS showed that the reaction was complete. The mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC (chromatographic column: Phenomenex Gemini NX 150*30mm*5um; mobile phase: [A%: water (TFA)-B%: ACN]; B%: 15%-45%, 20 minutes) to give a red solid 21-1 (50.00 mg, 0.09 mmol, yield 18.19%). LC-MS: 577.2 [M+H] + .
[0204] To a solution of 21-1 (50 mg, 0.087 mmol) in DCM (2.00 mL) was added TFA (0.70 mL, 9.14 mmol), and the resulting mixture was stirred at 25 ° C for 1 hour. LCMS showed that the reaction was complete. The mixture was concentrated under reduced pressure to give a yellow oily crude product 21-2 (40 mg, 0.084 mmol, yield 96.81%), which was used directly in the next step without purification. LC-MS: 477.2 [M + H] + .
[0205] To a mixture of 21-2 (15.0 mg, 0.025 mmol) and MRX-1657 (14.7 mg, 0.025 mol) in DMF (2.00 mL) was added NMM (0.014 mL, 0.127 mmol) and DMTMMT (8.33 mg, 0.025 mmol) at 25° C. The mixture was then stirred at 25° C. for 12 hours. LCMS showed that SM was completely consumed, and MS of the expected product was detected.
[0206] The reaction mixture was purified by prep-HPLC (chromatographic column: Agilent Poroshell EC C18 3*30 mm, 2.7 um; mobile phase: [A: H2O (0.1% TFA); B: MeOH]; B%: 15.00%-55.00%, 15.00 min) to give a red solid 21 (3.80 mg, 0.004 mmol, yield 14.4%).
[0207] LC-MS: 1038.3[M+H] + .
[0208] 1 H NMR (400MHz, DMSO-d6): δ8.90(s,2H),7.76(d,J=9.0Hz,1H),7.62-7.58(m,2H),7.37(d,J=10.0Hz ,1H),6.92(d,J=10.1Hz,1H),5.61(d,J=16.6Hz,1H),5.41(d,J=16.6Hz,1H),5.14(s,2H),4.44-4 .34(m,1H),4.17(s,2H),4.14-4.09(m,1H),3.19-3.13(m,3H),3.11-3.05(m,3H),2.63-2.54(m,2 H),2.52-2.45(m,2H),2.13-2.05(m,1H),1.97(td,J=13.3,6.7Hz,5H),1.86-1.67(m,8H),1.54(br dd,J=6.1,3.7Hz,2H),1.34(br d,J=2.9Hz,2H),1.05-0.98(m,16H).
[0209] Embodiment 22
[0210] To a solution of 22-1 (65.0 mg, 0.04 mmol) in DMF (2.00 mL) were added 21-2 (20.4 mg, 0.04 mol), NMM (0.02 mL, 0.17 mmol) and DMTMMT (13.43 mg, 0.04 mmol). The resulting mixture was then stirred at 25 °C for 12 hours. LCMS showed that the reaction was complete. The mixture was purified by prep-HPLC (chromatographic column: Phenomenex Gemini NX150*30mm*5um; mobile phase: [A: water (TFA)-B: ACN]; B%: 15%-45%, 20 minutes) to give a yellow solid 22 (11.81 mg, 0.01 mmol, yield 18.14%).
[0211] LC-MS: 762.2[1 / 2M+H] + .
[0212] 1H NMR (400MHz, METHANOL-d4): δ8.98-8.90(m,2H),8.40(br s,1H),8.30(br d,J=3.4Hz,1H),8.19(br d,J=7.4Hz,1H),7.95-7.89(m,1H),7.66-7.59(m,1H),7.56-7.50(m,1H),7.45(s,1H),7.30-7.26(m,5H),7.20(br dd,J=8.3,4.3Hz,1H),6.77(br d,J=9.9Hz,1H),5.58(s,1H),5.38(br s,1H),4.57-4.51(m,3H),4.47-4.42(m,3H),4.21-4.13(m,2H),4.07 (d,J=2.8Hz,1H),4.03(s,2H),3.96-3.92(m,3H),3.88-3.84(m,3H),3 .69-3.66(m,3H),3.61-3.56(m,30H),3.37(s,1H),3.36-3.35(m,3H),2.61-2.54(m,2H),2.41(q,J=7.3Hz,2H),2.00-1.89(m,4H),1.27(br t,J=7.1Hz,2H),1.00(t,J=7.3Hz,3H).
[0213] Example 23: Preparation of Antibody-Drug Conjugates (eg, ADC-1)
[0214] Antibodies for Exemplary ADCs
[0215] The antibodies of the example ADC compounds were prepared according to conventional methods, such as vector construction, eukaryotic cell transfection such as HEK2943 cell (Life Technologies Cat. No. 11625019) transfection, purification and expression. The prepared antibodies include trastuzumab light chain (SEQ. ID NO. 1), trastuzumab heavy chain (SEQ ID NO. 2), pertuzumab light chain (SEQ. ID NO. 3), pertuzumab heavy chain (SEQ. ID NO. 4), B7H3 antibody light chain (SEQ ID NO. 5) and B7H3 antibody heavy chain (SEQ ID No. 6).
[0216] General process of coupling
[0217] The prepared tris(2-carboxyethyl)phosphine aqueous solution (10 mM, 0.082 mL, 0.82 μmol) was added to the PBS buffered aqueous solution of the antibody (0.05 M PBS buffered aqueous solution, pH = 6.5; 2.5 mL, 9.96 mg / mL, 0.168 umol) at 37°C. The reaction solution was placed in a water bath shaker and shaken at 37°C for 3 hours, then the reaction was stopped. The reaction solution was cooled to 25°C in a water bath and diluted to 5.0 mg / ml. 2.0 ml of the solution was taken for the next reaction.
[0218] Connector-camptothecin compound (2.1mg, 2.02umol) is dissolved in 0.10mL DMSO, then added in 2.0mL above-mentioned solution.The reaction solution is placed in a water bath shaker, and the reaction is stopped after vibration at 25°C for 3 hours.The reaction solution is desalted and purified with a dextran G25 gel column (elution phase: 0.05M PBS buffered aqueous solution, pH=6.5, containing 0.001MEDTA), to obtain the PBS buffer solution of exemplary product ADC, which is stored at 4°C.
[0219] The drug loading analysis (UV method) of ADC was performed according to the method of U.S. Patent Application Publication No. US2021 / 00353764 (i.e., paragraph
[0702] ff).
[0220] Drug loading analysis of ADC (LC-MS method) was performed according to the method of US Pat. No. 11,572,414 (i.e., column 2, line 51 to column 3, line 15).
[0221] ADC aggregation levels were determined by size exclusion chromatography (SEC). All samples were filtered through 0.22 μm filters prior to HPLC-SEC analysis.
[0222] The HPLC method was performed as follows: Instrument: Thermo Ultimate 3000 Chromatographic column: Waters, XBridge BEH 3.5μm(7.8×300mm) Mobile phase: PBS containing 15% isopropanol, pH 7.4 Flow rate: 0.5 ml / min, 30 minutes.
[0223] The following ADCs were synthesized according to the general procedure described in Example 23.
[0224] Embodiment 24
[0225] In vitro cytotoxicity assay of camptothecin payload
[0226] Human lung adenocarcinoma cell lines A549, NCI-N87 and SK-BR-3 were used to evaluate the cytotoxicity of the small molecule fragments of the present invention. These cells were seeded into 96-well plates at 2000 cells per well. After overnight culture at 5% CO2 and 37°C, gradient dilutions of the compounds were added. After 3 days, the cell viability was assessed using the CellTiter-Glo luminescent cell viability detection kit produced by Promega Corp. and according to the manufacturer's instructions. The results are shown in Table 1 below.
[0227] Table 1 Cytotoxicity of compounds of formula (II) to A549 cells
[0228] As shown in Table 1, the compound of formula (II) is more potent than the control compound (Dxd).
[0229] Embodiment 25
[0230] In vitro cytotoxicity assay of ADCs
[0231] Cancer cell lines with different Her2 expression levels, including NCI-N87, Calu-3, SK-BR-3, CAPAN-1 and CFPAC-1 cells, were used to test the cytotoxicity of the ADC of the present invention. These cell lines were seeded into 96-well plates at 1000-4000 cells per well. After overnight culture at 5% CO2 and 37°C, gradient dilutions of the compounds were added. After 6 days, the cell viability was assessed using the CellTiter-Glo luminescent cell viability detection kit produced by Promega Corp. and according to the manufacturer's instructions. The results are shown in Table 2 below.
[0232] Table 2 In vitro cytotoxicity test of ADCs
[0233] Calu-3, NCI-N87 and SK-BR-3 are all Her2 high-expressing cancer cell lines, and CAPAN-1 and CFPAC-1 are reported as Her2 low-expressing cell lines. The ADCs of the present invention show comparable or higher cytotoxicity in Her2 high-expressing cancer cell lines, but surprisingly have significantly higher potency in Her2 low-expressing cell lines.
[0234] Embodiment 26
[0235] Rat PK study
[0236] Male SD rats, 180-200 g (BK Laboratory Animal Co., Ltd.), 3 rats / group. After intravenous administration (IV administration) of 1 mg / kg, blood samples were collected from the orbital vein into heparin tubes at 0.083, 0.5, 1, 2, 4 and 8 hours, and centrifuged at 10000 rpm for 3 minutes to obtain plasma. All samples were stored at -20°C until sent to Suzhou Chengyao Biotech Co., Ltd. for analysis. The results are shown in Table 3 below
[0237] Table 3. Rat PK results
[0238] As shown in Table 3, the compounds of the present invention have relatively poor stability in plasma. The Vss of the compounds of the present invention are significantly reduced, indicating that the drug is mainly concentrated in the plasma; the half-life is shorter, and it can be cleared faster, reducing the risk of damage to tissues outside the tumor. The reduction in Vss and the increase in the instability of free toxins are beneficial to ADCs because once the toxin is released from the ADC, it is possible to reduce the systemic exposure of the toxin, thereby alleviating the toxicity caused by the toxin. .
[0239] Embodiment 27
[0240] In vitro bystander killing of ADCs
[0241] The target cells SK-BR-3 and the GFP-labeled tool cells Flip in 293mGFP were inoculated or mixed and cultured for 1 day, and treated with a 4-fold serial dilution of the ADCs solution of the present invention for 5 days (mixed cells were prepared by mixing the two cells and inoculating at 40 μL / well, and the final density of SK-BR-3 was 750 cells / well, and the final density of Flip in 293mGFP was 250 cells / well). At the end of the treatment, the number of live Flip in 293mGFP cells was determined by high content screening (HCS) in DPC and FITC channels. The ADCs of the present invention have the effect of killing bystanders.
[0242] Embodiment 28
[0243] In vitro plasma stability study of ADC
[0244] A solution of 1.6 mg / mL of the ADC of the present invention was prepared and added to human plasma, and the resulting mixture was incubated at 37°C. 40uL samples were collected at each time point of 0, 6, 18, 24, 72 and 96 hours. After normal treatment, the free payload of the plasma samples was tested by LCMSMS method. The ADCs of the present invention have good stability in human plasma.
[0245] The LCMSMS method has the following characteristics: Instrument: Thermo Orbitrap Exploris240; Column: ACQUITY C18 1.7 μm (2.1 × 150 mm); Mobile phase: ACN containing 0.1% FA; Flow rate: 0.3ml / min.
[0246] Embodiment 29
[0247] In vivo efficacy studies of ADCs
[0248] The NCI-N87 cell line was used to create the CDX (cell line derived xenograft) NCI-N88 xenograft mouse model. Each 6-8 week old nu / nu nude mouse was inoculated with 10 7 The cells were injected subcutaneously into the right flank in 200 μL of Matrigel-NI-N87 cell suspension. The injection site was palpated three times a week until the average tumor size reached 300 mm as measured by digital calipers. 3 Animals were randomly divided into treatment groups. ADCs of the present invention were administered by intravenous injection. Tumor size was measured and recorded weekly. After treatment with ADCs of the present invention, tumor growth was greatly inhibited.
[0249] The complete representative data reveal the surprisingly superior therapeutic potential of the compounds described in the present application, with beneficial unexpected advantages in terms of efficacy, efficacy and bystander killing. The significant and surprising improvement in the in vivo efficacy of ADCs provided by the present application provides significant benefits for the treatment of humans or mammals, including but not limited to better clinical cure rates, reduced effective drug doses and reduced possible adverse reactions.
Claims
1. A ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, wherein: The ligand-drug conjugate comprises a drug unit D of formula I 1 : in: X is absent or selected from -O-, -S-, -S(O2)-, -S(O)-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1b -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)-, and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C8 cycloalkyl, C1-C8 alkyl, C1-C8 alkoxy, R 5 -(C1-C8 alkylene)-, amino, (C1-C8 alkyl)NHC(O)O-, (C3-C8 cycloalkyl)NHC(O)O-, (C1-C8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, (C1-C8 alkyl)C(O)O-, (C1-C8 alkyl)C(O)NH-; wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, C1-C8 alkoxy, each "C3-C8 cycloalkyl" and each "C1-C8 alkyl" are independently optionally substituted by one to four R 6 replace; R 3 and R 4 Independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl, amino; wherein C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R6; R 5 is selected from C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl; wherein C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C8 alkyl, C3-C8 cycloalkyl, aryl, heteroaryl; and a line with a dashed line therein represents a single bond or a double bond; n is 0 or 1.
2. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein: D 1 It is represented by formula II: X is -O- or -S-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)-, and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C6 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, R 5 -(C1-C3 alkylene)-, amino; wherein C1-C6 alkoxy, C3-C6 cycloalkyl and C1-C6 alkyl are independently optionally substituted by one to four R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl; wherein C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 5 is C1-C6 alkoxy or C3-C6 cycloalkyl; wherein C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C3 alkyl, C3-C6 cycloalkyl; And a line having a dashed line therein represents a single bond or a double bond.
3. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to claim 1 or 2, wherein: R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens; dashed lines represent double bonds.
4. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 3, wherein: D 1 Select from the following structures:
5. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 4, wherein: A ligand-drug conjugate of formula III or a pharmaceutically acceptable salt or solvate thereof: in: T is the targeting or binding ligand; L is a releasable linker; D 1 As defined in any one of claims 1 to 7; and m is selected from an integer or decimal between 1-10; optionally, m is selected from an integer or decimal between 3-8.
6. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to claim 5, wherein: L is -L 1 -L 2 -L 3 -L 4 -;in, L 1 Freedom to choose -CH2-C(O)-NR 7 -WC(O)-, -CH(COOH)-C(O)-NR 7 -WC(O)- and -C(O)-WC(O)-; wherein W and W 1 independently selected from the group consisting of C1-C8 alkylene, -(C1-C8 alkylene)-cycloalkylene, arylene, -arylene-(C1-C8 alkylene)-, heteroarylene and straight-chain (linear) heteroalkylene, wherein the straight-chain heteroalkylene contains 1 to 8 carbon atoms, and 1 to 6 heteroatoms selected from N, O and S, SO, SO2, and wherein the -(C1-C8 alkylene)-cycloalkylene, straight-chain heteroalkylene, arylene and heteroarylene are each independently optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein q is an integer selected from 1 to 6; wherein Z is selected from the group consisting of C1-C6 alkylene, C1-C6 alkenylene, C1-C6 alkynylene, arylene and heteroarylene; wherein Y is selected from -O-, -S-, -C(R 7 )(R 8 )- and heteroarylene group; wherein the above provided L 1 The left side of each of the groups is connected to T; L 2 Choose Free-NR 8 (CH2CH2O) p 1 CH2CH2C(O)-、-NR 8 (CH2CH2O) p 1 CH2CH2-、-NR 8 (CH2CH2O) p 1 CH2C(O)-、-S(CH2) p 1 C(O)-、-NR 8 -(CH2) p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O) p 1 CH2C(O), -NR 8 -(CH2) p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O) p 1 CH2CH2NHC(O)CH2OCH2C(O), -NR 8 (CH2CH2O) p 1 CH2CH2NHC(O)CH2OCH2C(O) and chemical bonds, where p 1 is an integer selected from 1 to 20; wherein p 2 is an integer selected from 1 to 3; wherein the L provided above 2 The left side of each of the groups is attached to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the L provided above 3 The left side of each group is connected to L 2 ; L 4 Choose Free-NR 9 (CR 10 R 11 ) t -、 and a chemical bond, wherein t is an integer selected from 1 to 6; wherein, in the presence of L 4 In the case of combination, the above provided L 4 The left side of each of the combinations is attached to L 3 on the right side, and L 4 The right side of each of the groups is attached to D 1 ; R 7 , R 8 , R 9 and R 12 are each independently selected from the group consisting of hydrogen, alkyl, halogenated alkyl, deuterated alkyl, and hydroxyalkyl; R 10 , R 11 , R 13 and R 14 are each independently selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; and R 15 Selected from -CH2CH2SO2CH3 and -CH2CH2N(CH3)2.
7. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to claim 5 or 6, wherein: L 1 Freedom to choose and -CH(COOH)-C(O)-NH-C6H4-(CH2)s 3 -C(O)- (where the left side of the group is connected to T), where s 1 is an integer selected from 2 to 8; s 2 is an integer selected from 1 to 3; s 3 is an integer selected from 1 to 8; q is an integer selected from 1 to 3; and Z is selected from the group consisting of C1-C6 alkylene, C1-C6 alkenylene and C1-C6 alkynylene; L 2 Choose Free-NR 8 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 8 (CH2CH2O) p 1 CH2C(O)-、-NR 8 -(CH2)p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O)p 1 CH2C(O) and chemical bonds; R 8 is selected from the group consisting of hydrogen, alkyl, halogenated alkyl, deuterated alkyl and hydroxyalkyl; 1 is an integer selected from 6 to 12; p 2 is an integer selected from 1 to 3; L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are selected from phenylalanine (F), glycine (G), valine (V), lysine (K), citrulline, serine (S), alanine (A), glutamic acid (E) and aspartic acid (D); alternatively, is a peptide residue consisting of 1, 2 or more phenylalanine and glycine; alternatively, is a peptide residue consisting of 4 amino acids; alternatively, is the peptide residue GGFG or VA; L 4 Yes - NR 9 (CR 10 R 11 ) t -、 Chemical bond; R 9 , R 10 , R 11 , R 12 , R 13 and R 14 are each independently selected from hydrogen and alkyl; R 15 is selected from -CH2CH2SO2CH3 and -CH2CH2N(CH3)2; t is 1 or 2; optionally L 4 It's a chemical bond.
8. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 5 to 7, wherein: L is selected from the following structures:
9. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 5 to 8, wherein: Selected from:
10. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 5 to 9, wherein: T is a targeting antibody or ligand that binds to an antigen; wherein the antibody is selected from a chimeric antibody, a humanized antibody and a human antibody; alternatively, wherein T is a monoclonal antibody.
11. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 5 to 10, wherein: T is a targeting antibody or ligand that binds to an antigen; wherein T is selected from anti-Her2 (ErbB2) antibody, anti-EGFR antibody, anti-B7H3 antibody, anti-c-MET antibody, anti-Her3 (ErbB3) antibody, anti-Her4 (ErbB4) antibody, anti-CD20 antibody, anti-CD22 antibody, anti-CD30 antibody, anti-D33 antibody, anti-CD44 antibody, anti-CD56 antibody, anti-CD70 antibody, anti-CD73 antibody, anti-CD105 antibody, anti-CEA antibody, anti-A33 antibody, anti-Cripto antibody, anti-EphA2 antibody, anti-G250 antibody, anti-MUC1 antibody, anti-Lewis antibody, Y antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-integrin antibody, anti-PSMA antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody, anti-mesothelin antibody, anti-ROR1 antibody or a fragment that binds to the antigen.
12. The ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 5 to 11, wherein: T is selected from trastuzumab, pertuzumab, nimotuzumab, enoxaparin, imatinib, ituzumab, pinatuzumab, brentuximab, gemtuzumab, bivacuzumab, lovatuzumab, cBR96, gebatumumab or a fragment that binds to an antigen; optionally, T is trastuzumab.
13. A compound of formula (IV) or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof, wherein: The formula (IV) is: L—D 1 (IV); Where D 1 Represented by formula I: in: X is absent or selected from -O-, -S-, -S(O2)-, -S(O)-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)-, and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C8 cycloalkyl, C1-C8 alkyl, C1-C8 alkoxy, R 5 -(C1-C8 alkylene)-, amino, (C1-C8 alkyl)NHC(O)O-, (C3-C8 cycloalkyl)NHC(O)O-, (C1-C8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, (C1-C8 alkyl)C(O)O-, (C1-C8 alkyl)C(O)NH-; wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, C1-C8 alkoxy, each "C3-C8 cycloalkyl" and each "C1-C8 alkyl" are independently optionally substituted by one to four R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C8 alkyl, C1-C8-alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl, amino; wherein C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 5 is selected from C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl; wherein C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C8 alkyl, C3-C8 cycloalkyl, aryl, heteroaryl; and a line with a dashed line therein represents a single bond or a double bond; n is 0 or 1; and where L is L 1a -L 2 -L 3 -L 4 -, L 1a Freedom to choose and COOH-WC(O)-; wherein W and W 1 independently selected from the group consisting of C1-C8 alkylene, -(C1-C8 alkylene)-cycloalkylene-, arylene, -arylene-(C1-C8 alkylene)-, heteroarylene and straight-chain (linear) heteroalkylene, wherein the straight-chain heteroalkylene contains 1 to 8 carbon atoms, and 1 to 6 heteroatoms selected from N, O and S, SO, SO2, and wherein the -(C1-C8 alkylene)-cycloalkylene-, straight-chain heteroalkylene, arylene and heteroarylene are each independently optionally further substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein q is an integer selected from 1-6; wherein Z is selected from the group consisting of C1-C6 alkylene, C1-C6 alkenylene, C1-C6 alkynylene, arylene and heteroarylene; wherein Y is selected from the group consisting of -O-, -S-, -C(R 7 )(R 8 )- and heteroarylene group; L 2 Choose Free-NR 8 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 8 (CH2CH2O)p 1 CH2CH2-、-NR 8 (CH2CH2O) p 1 CH2C(O)-、-S(CH2)p 1 C(O)-、-NR 8 -(CH2)p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O)p 1 CH2C(O), -NR 8 -(CH2)p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O)p 1 CH2CH2NHC(O)CH2OCH2C(O), -NR 8 (CH2CH2O)p 1 CH2CH2NHC(O)CH2OCH2C(O) and chemical bonds, where p 1 is an integer selected from 1 to 20; wherein p 2 is an integer selected from 1 to 3; wherein the L provided above 2 The left side of each of the groups is attached to L 1 ; L 3 is a peptide residue consisting of 2 to 7 amino acids, wherein the amino acids are optionally further substituted by one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; wherein the L provided above 3 The left side of each group is connected to L 2 ; L 4 Is the choice free-NR 9 (CR 10 R 11 ) t -、 and a group consisting of a chemical bond, wherein t is an integer selected from 1-6; wherein the L provided above 4 The left side of each combination is attached to L 3 on the right side, and the L 4 The right side of each group is attached to D 1 ; R 7 , R 8 , R 9 and R 12 are each independently selected from hydrogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; R 10 , R 11 , R 13 and R 14 are each independently selected from hydrogen, halogen, alkyl, haloalkyl, deuterated alkyl, and hydroxyalkyl; and R 15 Selected from -CH2CH2SO2CH3 and -CH2CH2N(CH3)2.
14. The compound according to claim 13 or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or a combination thereof, wherein: D 1 It is represented by formula II: X is -O- or -S-; R 1a Yes-NH-R 1b -O-, -NH-, -O-; optionally, R 1a is -NH- or -O-; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C6 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, R 5 -(C1-C3 alkylene)-, amino; wherein C1-C6 alkoxy, C3-C6 cycloalkyl and C1-C6 alkyl are independently optionally substituted by one to four R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6-alkoxy, C3-C6 cycloalkyl; wherein C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 5 is C1-C6 alkoxy or C3-C6 cycloalkyl; wherein C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C3 alkyl, C3-C6 cycloalkyl; And a line having a dashed line therein represents a single bond or a double bond.
15. The compound according to any one of claims 13 to 14, or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or a combination thereof, wherein: R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens; dashed lines represent double bonds.
16. The compound according to any one of claims 13 to 15, or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or a combination thereof, wherein: D 1 Select from the following structures:
17. A compound or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof according to any one of claims 13 to 16, wherein: L is L 1a -L 2 -L 3 -, L 1a Selected from where s 1 is an integer selected from 2 to 8; s 2 is an integer selected from 1 to 3; and q is an integer selected from 1 to 3; L 2 Choose Free-NR 8 (CH2CH2O) p 1 CH2CH2C(O)-、-NR 8 (CH2CH2O) p 1 CH2C(O)-、-NR 8 -(CH2)p 2 -(1H-1,2,3-triazole-1,4-diyl)-(CH2CH2O)p 1 CH2C(O) and chemical bonds, where R 8 is selected from the group consisting of hydrogen, alkyl, haloalkyl, deuterated alkyl and hydroxyalkyl; 1 is an integer selected from 6 to 12; p 2 is an integer selected from 1 to 3; wherein the L provided above 2 The left side of each of the groups is attached to L 1 ; L 3 is a peptide residue GGFG or VA; wherein the L provided above 3 The left side of each group is connected to L 2 ;as well as The above-mentioned L 3 The right side of each group is connected to D 1 .
18. The compound according to any one of claims 13 to 17, or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof, wherein: The compound is selected from the following structures:
19. A compound of formula (V) or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof, wherein: in: X is absent or selected from -O-, -S-, -S(O2)-, -S(O)-; R 1 Yes-NH-R 1b -OH, hydroxyl, amino; optionally, R 1 is a hydroxyl or amino group; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C8 cycloalkyl, C1-C8 alkyl, C1-C8 alkoxy, R 5 -(C1-C8 alkylene)-, amino, (C1-C8 alkyl)NHC(O)O-, (C3-C8 cycloalkyl)NHC(O)O-, (C1-C8 alkyl)NH-, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, (C1-C8 alkyl)C(O)O-, (C1-C8 alkyl)C(O)NH-; wherein azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, aziridine-1-yl, C1-C8 alkoxy, each "C3-C8 cycloalkyl" and each "C1-C8 alkyl" are independently optionally substituted by one to four R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl, amino; wherein C1-C8 alkyl, C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 5 is selected from C1-C8 alkoxy, C3-C8 cycloalkyl, aryl, heteroaryl; wherein C1-C8 alkoxy, C3-C8 cycloalkyl, aryl and heteroaryl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C8 alkyl, C3-C8 cycloalkyl, aryl, heteroaryl; and a line with a dashed line therein represents a single bond or a double bond; n is 0 or 1; Provided that when X is -O- or -S-, and the dashed line represents a single bond, then R 2 , R 3 and R 4 Not all H and not amino.
20. The compound according to claim 19 or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or a combination thereof, wherein: The compound represented by formula VII: in: X is selected from -O-, -S-, -S(O2)-, -S(O)-; R 1 Yes-NH-R 1b -OH, hydroxyl, amino; optionally, R 1 is a hydroxyl or amino group; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 is selected from hydrogen, halogen, hydroxy, cyano, nitro, C3-C6 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, R 5 -(C1-C3 alkylene)-, amino; wherein C1-C6 alkoxy, C3-C6 cycloalkyl and C1-C6 alkyl are independently optionally substituted by one to four R 6 replace; R 3 and R 4 independently selected from hydrogen, halogen, hydroxyl, cyano, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl; wherein C1-C6 alkyl, C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 5 is C1-C6 alkoxy or C3-C6 cycloalkyl; wherein C1-C6 alkoxy and C3-C6 cycloalkyl are independently optionally substituted by one to four R 6 replace; R 6 is independently selected at each occurrence from halogen, hydroxy, cyano, amino, C1-C3 alkyl, C3-C6 cycloalkyl.
21. The compound according to claim 19 or 20, or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof, wherein: R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens.
22. A compound according to any one of claims 19 to 21 or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof, wherein: X is -S-; R 1 Yes-NH-R 1b -OH or amino; optionally, R 1 It is amino; R 1b Selected from -C(O)-(C1-C6 alkylene)-, -C(O)-O-(C1-C6 alkylene)-, -C(O)-S-(C1-C6 alkylene)-, -C(O)-NH-(C1-C6 alkylene)-, -C(O)-(C3-C8 cycloalkylene)- and -C(S)-NH-(C1-C6 alkylene)-; wherein C1-C6 alkylene and C3-C8 cycloalkylene are independently optionally substituted by one to four R 6 replace; R 2 , R 3 and R 4 Independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 alkoxy, and wherein C1-C3 alkoxy and C1-C3 alkyl are independently optionally substituted with one to four halogens.
23. A compound according to any one of claims 19 to 22, or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or combination thereof, wherein: The compound is selected from the following structures:
24. A pharmaceutical composition comprising a therapeutically effective amount of the ligand-drug conjugate according to any one of claims 1 to 12 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
25. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 19 to 23 or a pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or a combination thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
26. Use of the ligand-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 1 to 12, or the pharmaceutical composition according to claim 24, in the preparation of a drug for preventing and / or treating cancer.
27. Use of the compound according to claims 28-34 or its pharmaceutically acceptable salt, solvate, tautomer, mesomer, racemate, enantiomer, diastereomer or a combination thereof, or the pharmaceutical composition according to claim 36 in the preparation of a medicament for preventing and / or treating cancer.
28. The use according to claim 26 or 27, wherein: The cancer is a tumor; optionally, the cancer is selected from the group consisting of breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer and lymphoma (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, relapsed anaplastic large cell lymphoma).
Citation Information
Cited By
Ligand-drug conjugate of camptothecin analogs and use thereof
WO2025124555A1
